

Helsinki University of Technology
Laboratory of Organic Chemistry
Espoo 2004

Department of Chemical Technology

**LIBRARY SEARCH-BASED DRUG ANALYSIS
IN FORENSIC TOXICOLOGY
BY LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY**

Merja Gergov



TEKNILLINEN KORKEAKOULU
TEKNISKA HÖGSKOLAN
HELSINKI UNIVERSITY OF TECHNOLOGY

Helsinki University of Technology
Laboratory of Organic Chemistry
Espoo 2004

Department of Chemical Technology

LIBRARY SEARCH-BASED DRUG ANALYSIS IN FORENSIC TOXICOLOGY BY LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY

Merja Gergov

Dissertation for the degree of Doctor of Science in Technology to be presented with due permission of the Department of Chemical Technology for public examination and debate in Auditorium KE 2 (Komppa Auditorium) at Helsinki University of Technology (Espoo, Finland) on the 29th of October, 2004, at 12 o'clock noon.

Helsinki University of Technology
Department of Chemical Technology
Laboratory of Organic Chemistry

Teknillinen korkeakoulu
Kemian tekniikan osasto
Orgaanisen kemian laboratorio

University of Helsinki
Department of Forensic Medicine
Forensic Chemistry Division

Helsingin yliopisto
Oikeuslääketieteen laitos
Oikeuskemian osasto

Distributor:
Helsinki University of Technology
P.O. Box 6100
FIN-02015 HUT

© Merja Gergov

ISBN 951-22-7278-4 (print)

ISBN 951-22-7279-2 (pdf)

Picaset Oy
Helsinki 2004

This study was carried out at the Department of Forensic Medicine, University of Helsinki, Finland.

Supervisors

Dr. John Robson

Perkin-Elmer SCIEX

Canada

Dr. Ilkka Ojanperä

University of Helsinki

Department of Forensic Medicine

Reviewers

Professor Risto Kostiainen

University of Helsinki

Faculty of Pharmacy

Dr. Tiia Kuuranne

United Laboratories Ltd.

Helsinki

Opponent

Professor Aldo Poletti

University of Pavia

Department of Legal Medicine & Public Health

Italy

Gergov, Merja. *Library Search-Based Drug Analysis in Forensic Toxicology by Liquid Chromatography–Mass Spectrometry.*

Keywords: liquid chromatography–mass spectrometry, screening, library search, drugs, forensic toxicology

ABSTRACT

Liquid chromatography–mass spectrometry (LC–MS) with electrospray (ES) ionization in the positive ion mode was applied to drug analysis in forensic toxicology. Several types of screening and confirmation strategies were developed, based essentially on searching of comprehensive MS libraries and databases that were created in-house for the purpose.

Two spectral libraries, both containing spectra for approximately 400 drugs, were created. Spectra for the LC–MS/in-source collision-induced dissociation (CID) library were acquired by continuously switching between low (25 V) and high (90 V) orifice voltages during the run, and the summed mass spectra were added to the library. A library for liquid chromatography–triple quadrupole mass spectrometry (LC–MS/MS) was created by obtaining product ion spectra at a collision energy of 35 eV, and additionally at 20 eV or 50 eV, if the latter were more informative. The product ion spectra were reproducible in the long-term, based on a four-year experiment. Comparison of two libraries, independently created with similar instruments in different laboratories, showed that the libraries were fully compatible. Comparison of spectra obtained with different manufacturers' instruments suggested that after standardization of collision energy and gas pressure, LC–MS/MS spectral libraries are suitable for interlaboratory use.

The libraries were utilized in two fully automated methods for selected drug groups, comprising screening and confirmation. Analysis of 16 β -blocking drugs in urine involved two-step MS analysis, including a screening step based on monitoring of protonated molecules and a confirmation step based on LC–MS/MS product ion spectra. A method for simultaneous screening and quantitation of 18 antihistamine drugs in blood involved multiple-reaction monitoring (MRM) for screening and quantitation and product ion spectra for confirmation of the drugs. The antihistamines were identified and quantified at concentrations ranging from subtherapeutic to toxic in blood. A data-dependent experiment (DDE) was utilized for automation of both procedures, from starting the sample batch to printing of the library search results.

Two different approaches for comprehensive screening of drugs were developed. A method for simultaneous screening of 238 drugs in blood was developed using LC–MS/MS with multiple-reaction monitoring. Identification was based on RT and the presence of protonated molecule and one representative fragment ion. The method was shown to be sufficiently selective and sensitive to allow the majority of the drugs to be detected at therapeutic concentrations. Another approach was based on accurate mass determination with liquid chromatography–time-of-flight mass spectrometry (LC–MS/TOF), using a target database of monoisotopic masses for 433 drugs. The method was tentatively suitable for rapid screening of drugs in urine even without referral to primary reference standards.

ABBREVIATIONS

APCI	Atmospheric pressure chemical ionization
CE	Collision energy
CID	Collision-induced dissociation
DAD	Diode array detection
DDE	Data-dependent experiment
DLI	Direct liquid introduction
EI	Electron impact
ES	Electrospray
GC	Gas chromatography
GC–MS	Gas chromatography–mass spectrometry
IDA	Information dependent acquisition
LC	Liquid chromatography (high performance)
LC–MS	Liquid chromatography–mass spectrometry
LC–MS/MS	Liquid chromatography–tandem mass spectrometry
LLE	Liquid-liquid extraction
LOD	Limit of detection
LOI	Limit of identification
LOQ	Limit of quantitation
MRM	Multiple-reaction monitoring
MS	Mass spectrometry
OPLC	Overpressured layer chromatography
Q-TOF	Quadrupole-time-of-flight instrument
Q-trap	Quadrupole-ion trap instrument
RP	Reversed phase
RSD	Relative standard deviation
RT	Retention time
SPE	Solid-phase extraction
SIM	Selected ion monitoring
TIC	Total ion chromatogram
TLC	Thin-layer chromatography
TOF	Time-of-flight
TS	Thermospray
UV	Ultraviolet (spectrometry)

LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following five articles, which in the text are referred to as **I-V**:

- I** Gergov M., Robson J.N., Duchoslav E., Ojanperä I., Automated liquid chromatographic/tandem mass spectrometric method for screening β -blocking drugs in urine, *J. Mass Spectrom.* **35** (2000) 912-918.

- II** Gergov M., Robson J.N., Ojanperä I., Heinonen O.P., Vuori E., Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry, *Forensic Sci. Int.* **121** (2001) 108-115.

- III** Gergov M., Weinmann W., Meriluoto J., Uusitalo J., Ojanperä I., Comparison of product ion spectra obtained by liquid chromatography/triple quadrupole mass spectrometry for library search, *Rapid Commun. Mass Spectrom.* **18** (2004) 1039-1046.

- IV** Gergov M., Ojanperä I., Vuori E., Simultaneous screening for 238 drugs in blood by liquid chromatography–ionspray tandem mass spectrometry with multiple-reaction monitoring, *J. Chromatogr. B* **795** (2003) 41-53.

- V** Gergov M., Boucher B., Ojanperä I., Vuori E., Toxicological screening of urine for drugs by liquid chromatography/time-of-flight mass spectrometry with automated target library search based on elemental formulas, *Rapid Commun. Mass Spectrom.* **15** (2001) 521-526.

The articles are referred to in the text by their Roman numerals. Data published and discussed here for the first time are referred to as **VI**.

The author's contribution to the publications

- I** The author was the main contributor in defining the research plan. The author carried out experiments and interpreted the analysis results. The author carried out all library runs for the 400 drug substances and created the libraries. The author wrote the manuscript.
- II** The author defined the research plan together with the coauthors. The author carried out the experiments, interpreted the results, and wrote the manuscript.
- III** The author defined the research plan for all the participating laboratories, carried out the experiments of the University of Helsinki, interpreted the results of all laboratories, and wrote the manuscript.
- IV** The author defined the research plan, carried out the experiments, and wrote the manuscript.
- V** The author defined the research plan together with the coauthors. The author participated in the development of the software and in carrying out the experiments in USA. The author was the main contributor in the interpretation of the results and wrote the manuscript.

Table of Contents	Page
ABSTRACT	
ABBREVIATIONS	
LIST OF ORIGINAL PUBLICATIONS	
1. INTRODUCTION	11
2. REVIEW OF THE LITERATURE	13
2.1 Sample preparation	13
2.2 Liquid chromatography prior to mass spectrometry	14
2.3 Ionization by electrospray	14
2.4 LC–MS/in-source CID spectral libraries	15
2.5 LC–MS/MS product ion spectral libraries	17
2.6 Methods in toxicological screening	19
2.7 Quantitation in LC–MS/MS/MRM	22
3. AIMS OF THE STUDY	24
4. EXPERIMENTAL	25
4.1 Standards and reagents	25
4.2 Samples	25
4.3 Instrumentation	25
4.4 Methods	26
4.4.1 <i>Extraction</i>	26
4.4.2 <i>Liquid chromatography</i>	26
4.4.3 <i>Mass spectrometry</i>	27
5. RESULTS	29
5.1 Automated screening and confirmation	29
5.2 Quantitative analysis	32
5.3 Reproducibility of MS/MS spectral library search	33
5.4 Comprehensive screening by multiple-reaction monitoring	35
5.5 Comprehensive screening by accurate mass measurement	35

6. DISCUSSION	40
7. CONCLUSIONS	45
ACKNOWLEDGEMENTS	47
REFERENCES	48

1. INTRODUCTION

In forensic and clinical toxicology, demands for analytical laboratories are growing along with the rapidly changing drug scene. The toxicologist must be able to detect and identify drugs and poisons that could be abused or cause intoxication and to quantitate them at concentration levels that may vary tremendously. In these types of examination, comprehensiveness and positive identification are of primary importance. Screening methods are needed in toxicology, including areas such as homicides, suicidal deaths, traffic accidents, drugs and driving monitoring, work place drug testing, doping control, date-rape drugs, poisoned patients etc.

Screening routines should be designed to detect as many drugs as possible within relevant drug classes, e.g. antidepressants, neuroleptics, benzodiazepines, analgesics, anaesthetics, β -blockers, antihistamines and drugs of abuse. After therapeutic doses, drugs may be found at low concentrations, from a few micrograms to several milligrams per litre in the blood, with lethal concentrations being 10 to 100 times higher. Some drugs are metabolized very quickly (e.g. heroin) and are not detectable at all in the blood. Metabolites of the parent drugs may, however, persist for longer periods of time in the urine, and therefore urine samples are usually also screened for metabolites. Most of the toxicologically relevant drugs are small stable organic compounds, ranging from 100 to 700 in molecular weight, the majority of which are basic, fairly hydrophobic and contain nitrogen. Various polar (e.g. atenolol), nonvolatile (digoxin) and thermally labile (zopiclone) substances require special attention.

Standards for the reliability and accuracy of analytical methods are very high, because the results may be used in courts as evidence. To obtain results with a high level of confidence, the entire procedure from sample treatment to detection methods should be sensitive and rugged at the same time. Ruggedness is essential, because of the inconstant quality and inestimable contents of post mortem samples. Sensitivity becomes critical not only because the concentration of toxicants may be very low, but also because sample volume may often be very limited.

A successful analytical method is a seamless combination of extraction, separation, detection and reporting. The conventional approach has been to extract small groups of compounds separately and then to analyse the extracts by target methods dedicated to each compound group. This is a time-consuming and tedious procedure. Therefore, the trend has been towards using universal multistep extraction methods that would cover different categories of drugs. Once such combined extracts with chemically different compounds are available, it leads to the next challenge of how to separate and

detect them in a single method. No single technique or instrument is yet available that would cover all chemically different drugs specifically, selectively, sensitively, reliably and preferably also automatically.

Techniques that are currently used in forensic and clinical toxicology include immunoassays, thin-layer chromatography (TLC), overpressured layer chromatography (OPLC), liquid chromatography with ultraviolet or diode-array detection (LC–UV or LC–DAD) and gas chromatography (GC) with different detectors. Immunoassays are feasible for preliminary screening, but the positive results must be confirmed using other techniques. The benefit of classical TLC is simple and inexpensive instrumentation and suitability for many types of compounds, but it lacks specificity, even when corrected R_f values, *in situ* UV spectra and colour reactions are used for identification. GC has been the method of choice, especially for screening basic drugs using nitrogen-selective detection. GC coupled with mass spectrometry (GC–MS) has been given the status of gold standard in confirmation analysis after different screening procedures. Its high separation power and commercially available huge electron impact (EI) spectral libraries are the unquestionable benefits of GC–MS; however, its suitability for polar, thermolabile or high-mass molecules is restricted. Moreover, sample preparation often requires complex and time-consuming extraction procedures including derivatization, and sensitive screening in the selected ion monitoring (SIM) mode is only possible for 30-40 compounds per method. LC has the benefit of being suitable for several types of compounds, because basically the compounds only have to be dissolvable in a suitable solvent. However, the separation power of LC is limited, and a detection method more specific than UV or DAD is needed for reliable identification. Since the early 1990s, coupling of LC with MS became common in forensic toxicology, but only recently has the scope of LC–MS been widened from target analysis to comprehensive screening and confirmation.

2. REVIEW OF THE LITERATURE

2.1 Sample preparation

Drugs are present in blood plasma and inside the haemic cells and should be released before extraction. Hydrophilic drugs are usually free in solution, whereas lipophilic drugs are noncovalently bound to proteins or particles. Noncovalent bonds can be broken by dilution, pH change or organic solvents. Blood analysis is very important in forensic toxicology, because drug concentrations in blood represent an acute drug effect and can be used to estimate the probability of intoxication. Conversely, many drugs and metabolites are present in urine as conjugates covalently bound to glucuronic acid, sulphate or glycine, and must be released prior to extraction, e.g. by enzymatic hydrolysis.

The literature available since 1990 concerning the extraction techniques suitable for systematic toxicological analysis was reviewed by Drummer¹ and Polettini.² Three different methods have commonly been used to isolate drugs from biological material: liquid-liquid extraction (LLE), solid-phase extraction (SPE) and protein precipitation/dilution. Precipitation of whole blood or dilution of urine e.g. with acetonitrile or methanol, are rapid and simple procedures, but large amounts of matrix material are co-extracted and may interfere with the analysis. Additionally, the analytes may stick into the surface of particles during precipitation, which lowers the recovery. SPE is a commonly used extraction method that enables sample preparation in batches and automation of the extraction procedure, and generally provides good selectivity and clean extracts.³ Mixed-mode columns (reversed phase (RP) + ion exchange) are especially feasible for extraction of a broad range of chemically different compounds. SPE is very suitable for urine samples, which are homogeneous and thereby do not cause blockage of the extraction columns. It can also be used for autopsy blood;^{4,5} however, the material may be lumpy and sometimes even decayed, causing blockage of the SPE column, which can be decreased by sonication before SPE.⁶⁻⁸ Plasma would be a less complicated matrix, but in postmortem samples it cannot be separated from whole blood due to haemolysis. Therefore, LLE is more generally suitable for autopsy blood samples.⁹ In screening methods, compounds with different polarities are analysed, and reasonable coverage with LLE can only be obtained through separate extraction of acidic and basic compounds. To shorten the total analysis time, the acidic and basic extracts can be combined and subjected simultaneously to MS detection.

2.2 Liquid chromatography prior to mass spectrometry

The status of LC–MS was reviewed by several authors.^{10–16} Due to its universality, LC is a very suitable separation technique for multicomponent analysis. The benefit of using LC instead of GC is the feasibility of analysing also thermolabile, polar and volatile compounds without time-consuming extraction and derivatization procedures. On the other hand, the separation efficiency is not as good as in GC, however, this disadvantage is not critical because MS provides good specificity and selectivity. The only special demands are the use of volatile buffers (e.g. ammonium acetate) and low flow rates (< 300 µl/min in an ion spray), which allows the liquid to be evaporated in the ion source. In contrast to the first estimations, the chromatographic separation step is important even when a mass spectrometer is used as a detector. Typically, a slow gradient (10 - 30 minutes) and reversed phase column (10 to 15 cm) have been used to obtain acceptable separation of various types of compounds in a reasonable total analysis time.

2.3 Ionization by electrospray

The first scientific report of charged aerosols generated by electrospray (ES) at atmospheric pressure was described by Zeleny in 1917.¹⁷ During the 1960s and 1970s, several research groups worked on early models of ES and chemical ionization (CI) interfaces for MS, e.g. Dole *et al.*,¹⁸ Tal’Rose *et al.*,¹⁹ Horning *et al.*,²⁰ Arpino *et al.*,^{21,22} and Iribarne and Thomson.²³ One of the earliest combinations of ES with MS was introduced by Yamashita and Fenn in 1984.²⁴ Twenty years later, LC–MS techniques also became popular in forensic toxicology. In an overview on interfacing LC with MS, van Bocxlaer *et al.*¹⁴ distinguished between three principally different approaches: 1) removal of the mobile phase followed by vaporization and ionization of the analytes, 2) direct ionization from the effluent stream and 3) nebulization of the effluent followed by chemical ionization or ion evaporation. For nebulization, four different techniques are used: DLI (direct liquid introduction), TS (thermospray), ES (electrospray) and APCI (atmospheric pressure chemical ionization). Recently, APPI (atmospheric pressure photoionization) has also been used for ionization.²⁵ Instrumentation for ES and APCI is commercially available, and the majority of recent papers concerning practical applications of LC–MS in forensic toxicology deal with ES or APCI. Moreover, ES and APCI were predicted to be of major future interest.^{13,14} In APCI, a discharge electrode is used to ionize solvent molecules, which after several ion-molecule reactions, transfer a charge to the analytes.

The ES ion source consists of a capillary nebulizer tube to which a voltage is applied. The sample solution is introduced via a syringe pump or LC pump. When LC is used, the flow rate is usually tens or hundreds of microlitres per minute in a normal column (i.d. 1-5 mm), thus requiring splitting of the flow down to less than 10 $\mu\text{l}/\text{min}$. In 1987, Bruins *et al.*²⁶ described a pneumatically assisted ES, in which a drying gas (e.g. nitrogen) is applied to assist droplet formation and evaporation, and splitting is not needed. This type of ES is called ionspray, and has been used in most modern toxicological applications as well as in the present study.

In an ES ion source, molecules are ionized in the liquid phase and evaporated to the gas phase under atmospheric pressure, then introduced into a mass spectrometer. The formation of gas-phase ions is assumed to occur by direct emission of ions from microdroplets during ion evaporation²³ or by coulombic fission²⁷ or by both ways simultaneously. According to the ion evaporation theory, solvent evaporates from the charged droplets and consequently the droplets diminish in size until finally, at the Rayleigh limit, the formation of gas-phase ions occurs directly from the small droplets. In the coulombic fission theory, evaporation of the solvent causes an increase in charge repulsion at the surface of the droplets, and the coulombic strain is released by droplet fission.

The response in ES is concentration-sensitive and not mass flow-sensitive, and favours low flow rates,²⁸ which enables the use of small-bore columns with high resolution. ES is also a soft ionization technique, and therefore molecules are only slightly, or not at all, fragmented. Protonated $[\text{M}+\text{H}]^+$ or deprotonated $[\text{M}-\text{H}]^-$ molecules are mainly observed, depending on the polarity of the electric field applied to the tip of the capillary needle. However, some structural information can be obtained, e.g. using the so-called in-source collision-induced dissociation (in-source CID) techniques, in which molecules are fragmented inside the ion source using increased voltage of the declustering potential lens (orifice voltage) (**Figure 1**).

2.4 LC–MS/in-source CID spectral libraries

GC–MS libraries have been used for the identification of unknown compounds for years. This has been possible because EI spectra are very reproducible, and therefore several huge commercial spectral libraries are available that include as many as several hundred thousand compounds. For example, the NIST 02 (National Institute of Standards and Technology, <http://sisweb.com>) contains EI spectra for approximately 147 000 compounds. The situation is different with single-quadrupole LC–MS, in which fragmentation is affected by several parameters because it occurs inside the ion source; thus,

common LC–MS libraries have not been established until recently. Several groups²⁹⁻³⁴ investigated the effect of different variables, such as mobile phase composition, pH, flow rate, analyte concentration,




Figure 1. In-source CID fragmentation in an electrospray ion source.

heater gas temperature, ion source dirtiness and needle position. In addition to the most important variable (declustering potential), needle position and heater gas temperature also significantly affect the appearance of the spectra, while the other variables have more effect on the intensity of mass signals. The settings of these parameters are not always reproducible, and it has been demonstrated that comparison of in-source CID spectra between instruments demands effective tuning of the instruments. Glafenine and haloperidol were suggested as tuning compounds.^{29-31,35-36} The reproducibility of spectra has also been questionable; indeed, poor reproducibility was reported even within a single instrument.³²

Declustering potential (the difference between voltages at the orifice plate and skimmer, **Figure 2**), which mainly affects in-source CID spectra, can be very effectively used to obtain fragmentation, and several spectral libraries have been created based on summarizing spectra obtained with and without fragmentation (**Table 1**). These summarized spectra contain both the protonated molecule $[M+H]^+$ and its main fragments, and thus a lot of information. However, in practical work with real samples a problem arises from co-eluting compounds, which leads to a summary spectrum of all these compounds. This type of unknown multicomponent spectrum cannot be resolved from any library.

Comparisons of spectra between different quadrupole mass spectrometers have been reported both with in-source CID spectra and with MS/MS product ion spectra. In-source CID spectra were shown

to contain the same fragments, but significant differences in their relative ion ratios were noted even after tuning of the instruments.³²⁻³⁷

2.5 LC–MS/MS product ion spectral libraries

A triple-quadrupole instrument (**Figure 2**) consists of three quadrupoles in sequence. A selected mass range can be scanned with the identical mass filter quadrupoles Q1 and Q3. The center quadrupole (Q2) is used for fragmentation and is referred to as the collision cell. The collision energy (CE) is the difference in voltages between the collision cell offset and entrance rod (Q0) potential.




Figure 2. Schematic structure of a triple-quadrupole mass spectrometer (Sciex).

The appearance of an MS/MS spectrum in triple-quadrupole instruments is not dependent on the design of the ion source, because fragmentation occurs after it inside the second quadrupole, i.e. in the collision cell (**Figure 3**, Q2), but the efficiency of ionization and the transfer of ions into the gas phase affects the intensity of the entire spectrum. Once a precursor ion is selected in the first quadrupole (Q1) and introduced into the collision cell, the fragmentation is affected by CE and collision gas pressure. Both these parameters can be exactly and reproducibly adjusted. The earliest standard operation protocols for acquiring MS/MS spectra with triple quadrupoles were established twenty years ago,³⁸ and later it was shown that with fixed settings it is possible to create spectral libraries that are instrument-independent.³⁴ Recently, this was also shown to be possible with modern LC–MS/MS triple-quadrupole instruments.⁴⁰

The question of using peak intensity ratios as an identification criterion has been under discussion among research groups developing spectral libraries. While ion ratios vary depending on the ionization and fragmentation techniques used, a new approach was developed to ignore their effect on

library search results: a library was created by putting the m/z values of the fragments in the library at 100% or 50% intensity only, which was chosen depending on the signal peak area counts. Using this simplified procedure, MS/MS spectra obtained with different triple-quadrupole instruments and with an ion trap mass spectrometer, were fully comparable.^{41,42}




Figure 3. Acquisition of an MS/MS product ion spectrum in a triple-quadrupole mass spectrometer.

Several laboratories have developed LC–MS/in-source CID and LC–MS/MS spectral libraries with quadrupole instruments for in-house use, but few of these have been published although some are currently available on the Internet. Some of the first published spectral libraries are summarized and described briefly in **Table 1**.

Table 1. Some of the first published LC–MS spectral libraries. The number of compounds may have been updated since establishment of the library.

Instrument Type	Fragmentation Type	Compound Type	Approx. number of Compounds	Reference
Single quadrupole	In-source CID	Drugs	Not available	Josephs, 1995 ⁴³
Single quadrupole	In-source CID	Drugs, toxicants	600	Marquet, 1998 ⁴⁴
Single quadrupole	In-source CID	Pesticides, explosives	90	Schreiber, 2000 ³¹
Single quadrupole	In-source CID	Drugs	400	Weinmann, 1999 ²⁹
Single quadrupole	In-source CID	Pesticides, drugs	38	Hough, 2000 ³⁴
Triple quadrupole	MS/MS	Pesticides	73	Slobodnik, 1996 ⁴⁵
Triple quadrupole	MS/MS	Pesticides	115	Kienhuis, 2000 ⁴¹
Triple quadrupole	MS/MS	Drugs	400	Weinmann, 2000 ⁴⁰
Ion trap	MS/MS	Miscellaneous	Not available	Sander, 2000 ⁴⁶
Ion trap	MS/MS	Drugs	Not available	Fitzgerald, 1999 ⁴⁷
Ion trap	MS/MS	Natural products	Not available	Sanders, 2000 ⁴⁸
Ion trap	MS/MS	Miscellaneous	600	Baumann, 2000 ⁴⁹

The number of compounds mentioned in **Table 1** are those originally reported and have probably increased, since these libraries are updated continuously. As can be concluded from the variety of libraries, cooperation in combining existing libraries or creating new and comprehensive ones will not be easy, but would be beneficial for all laboratories. Quadrupole-ion trap (Q-trap) libraries have also been created, and recently it was shown that a library, set up with a triple quadrupole instrument, can be transferred to a linear Q-trap mass spectrometer.⁵⁰

Long-term reproducibility of spectra is a critical issue, because continuity and high confidence level are demanded in the identification of unknowns in forensic cases. With the exception of one study,³² good reproducibility over three to eight months was reported for LC–MS/in-source CID spectra^{33,34} and over 30 months for LC–MS/MS spectra.⁴⁰ However, taking into account the huge amount of labour needed to create a large spectral library, reproducibility should be ensured for years, as has been established for GC–MS spectral libraries.

2.6 Methods in toxicological screening

Several strategies for screening drugs from forensic samples with LC–MS have been proposed in the literature. Identification has been based on single quadrupole, triple quadrupole, TOF, Q-TOF or Q-trap techniques. Prescreening (or survey scanning) is a critical step. With single quadrupoles, full scan or SIM can be used, and with triple quadrupoles multiple-reaction monitoring (MRM) is also possible. The various modes of operation of quadrupole instruments are illustrated in **Figures 4-6**.




Figure 4. Full scan mode of a single quadrupole mass spectrometer.




Figure 5. Selected ion monitoring mode of a single quadrupole mass spectrometer.




Figure 6. Multiple-reaction monitoring mode of a triple-quadrupole mass spectrometer.

The first “general unknown” procedure using LC–MS/in-source CID was presented by Marquet *et al.* 1998,⁴⁴ and was later developed further by the same authors.^{16,30,51} The method included LC-reversed phase chromatographic separation and detection by a single mass spectrometer with ionspray interface and using the in-source CID fragmentation mode. Four separate spectra were generated simultaneously, two positive and two negative spectra at low (weak fragmentation) and at high (extensive fragmentation) orifice voltage. After acquisition, the low- and high-energy spectra were summed at both polarities, and these two reconstructed spectra were searched against positive and negative mass spectral libraries. Similar type of methods were also presented by others.^{29,52,53} The benefit of using in-source CID is that while acquisition is performed in full-scan mode, it is not restricted to previously selected compounds. The moderate price of single mass spectrometers makes them an attractive choice for routine laboratories. The disadvantage, however, is that co-eluting compounds result in interfering spectra, making them unsearchable from the libraries of pure compounds. It has also not been possible to reproduce these spectra without extensive tuning of the instrument, and differences in fragmentation degree between separate instruments were reported.³⁵ One additional difficulty has been the detection of small peaks from the background; however, a new data-handling procedure was recently developed to overcome this problem.⁵¹

Another screening strategy, based on monitoring of selected ions in a broad scope, was first presented by Fillion *et al.* 1995.⁵⁴ The method was developed for 189 pesticide residue compounds from foods using GC–MS/SIM, but this strategy was also applicable to LC–MS/MS/MRM with certain modifications. Two injections in selective-ion mode were needed to cover all compounds, and the criteria for a positive identification were correct retention time (RT) and ion ratio of the target ion to at least one qualifier ion. During the first injection, the chromatographic run was split into 35 time windows and the second injection into 20 time windows. Several authors applied this method to LC–MS/MS to analyse a limited number of drugs from biological samples,⁵⁵⁻⁵⁸ but the results of only one broad screening method have been so far published.⁵⁹ There are several benefits of using MS/MS

instead of single MS/in-source CID in screening: higher sensitivity, better specificity because the fragments originate only from the selected precursor ion, possibility of linking product ion scanning and library searching for confirmation of the identity of the drugs and the option of including quantification in the automatic procedure. On the other hand, one weak point is that no matter how many compounds the MRM procedure covers, it never constitutes “general unknown” screening because the compounds monitored are selected in advance. Moreover, the scanning speed of the instrument may set a limitation on the number of compounds that can be included in the method. The high price of instrumentation may also restrict its applicability. Very recently it was reported that specificity of a triple quadrupole can be remarkably increased using enhanced resolution, with the mass peak full width at half maximum height (fwhm) set at 0.1 Da, which improves mass accuracy from the conventional 0.7 Da to as high as 0.003 Da.⁶⁰ This feature has so far been applied only in metabolite identification, but it would be an attractive enhancement for broad screening of drugs with LC–MS/MS/MRM.

Time-of-flight (TOF) mass spectrometry is an alternative choice for multicomponent drug analysis of biological samples. In single-MS time-of flight instruments (LC–MS/TOF) (**Figure 7**), quadrupoles focus the ion beam on the TOF analyser, which is positioned perpendicularly, and ions are pulsed into the flight tube by applying voltage. The ions separate according to their m/z values, high-mass ions having longer flight times.




Figure 7. Schematic structure of a single-MS time-of-flight mass spectrometer (Applied Biosystems).

LC–MS/TOF provides relatively high mass accuracy (~5 ppm) and reasonable resolution (5000-10000 fwhm) at moderate cost, and has been used in combinatorial chemistry and in analysis of drugs and their metabolites.⁶¹⁻⁶³ An obvious benefit of TOF mass spectrometers is that they acquire the entire mass spectrum simultaneously instead of scanning at preset steps. Any compound of interest can be extracted

after acquisition from the original run without the need for re-extracting and reinjecting the sample. This is beneficial when the sample amount is limited or when there is no sample left for further studies. Acquiring the entire mass spectrum is an important feature when very large numbers of compounds are screened. In such applications, maintaining hundreds of reference compounds is very expensive and laborious. Even though LC–MS/TOF instruments provide accurate molecular weight, screening methods using LC–MS/TOF instruments need very good chromatographic separation, because co-eluting peaks, as well as unintentional in-source CID fragmentation, lead to a mixture of mass peaks of unknown origin because the precursor ion cannot be specifically selected. Another drawback of TOF instruments is that they are not as reliable in quantification as quadrupole instruments.

Techniques involving tandem-MS quadrupole-time-of-flight (LC–MS/MS/Q-TOF) also provide structural information. Few studies are available that describe broad screening procedures performed with an LC–MS/MS/Q-TOF instrument^{64–66} although sophisticated methods including screening and confirmation in a single run, can be developed. In one of these methods,⁶⁵ the first step was a survey scan of the desired mass range with single MS. All masses exceeding the preset threshold of intensity were then automatically selected for precursor ions to acquire the product ion scan with LC–MS/MS/Q-TOF. The product ion scan was then acquired with different collision energies, because the most favourable fragmentation conditions are not known in advance. Based on these accurate masses, the elemental composition of specific peaks was calculated and searched against the Merck Index or laboratory's own list of relevant compounds and their accurate masses. Finally, the product ion spectra obtained were searched against an in-house spectral library. It was also possible to include automatic quantitation in the procedure, based on the accurate mass of the precursor ion.⁶⁵ LC–MS/MS/Q-TOF screening methods have higher selectivity, sensitivity and reliability compared with the traditional GC–MS and LC–MS methods. However, one limiting factor is still the ion source, because none of the available sources is universal. From the practical point of view, maintaining mass accuracy at high level demands continuous calibration and stable external temperature conditions. The high price of instrumentation and complexity of the method can also be obstacles preventing this technique from becoming a routine application in forensic laboratories.

Liquid chromatography coupled with ion trap mass spectrometry (LC–MS/Q-trap) was used in forensic toxicology to identify a wide range of basic drugs from urine samples by Fitzgerald *et al.* in 1999⁴⁷ and was recently also applied to broad screening of drugs.^{50,68} The mass accuracy in an LC–MS/Q-trap instrument (~20 ppm for pure compounds at $m/z < 500$ Da) is much better than in conventional triple quadrupoles (fwhm = 0.7 Da), but not as good as that of LC–MS/TOF and LC–MS/MS/Q-TOF (~5

ppm). In these two LC–MS/Q-trap screening methods,^{50,68} the survey scan is performed in MRM mode or in enhanced-resolution SIM mode followed by the product ion scan automatically started by information dependent acquisition (IDA). Product ion spectra were acquired at three preselected collision energies in positive mode⁵⁰ or at two energies in positive and negative ion mode.⁶⁸ The spectra were then searched against a correspondingly created mass spectral library. Both of these preliminary methods showed a high potential for use of ion traps in analytical toxicology. The enhanced mass accuracy and better sensitivity obtained at no increase in cost compared with quadrupoles makes LC–MS/Q-trap an interesting new alternative for forensic screening.

2.7 Quantitation in LC–MS/MS/MRM

LC–MS provides the specificity and sensitivity demanded for an accurate quantitation method for a wide range of compounds. LC–MS/MS with multiple-reaction monitoring (MRM) also provides quantitation of such substances that are not chromatographically separated, because it can be used to filter the interfering ions twice, both in the first and in the third quadrupole. The procedure very effectively cleans the chromatogram, and therefore integration of peak areas is accurate. However, the co-eluting interfering substances from the matrix do not exit the system but become “invisible”. Therefore, ion suppression may occur even though it is not seen in any way in the chromatograms. Ion suppression is caused by compounds in the sample matrix that prevent analytes from reaching the surface of the droplets during the ion-evaporation process. On the other hand, part of the analytes may also precipitate during solvent evaporation or remain unevaporated and thereby never reach the mass spectrometer. In addition, if the protons in the eluent are more attracted by the matrix, then some of the analytes will not be ionized and will be drawn out of the interface by the vacuum.⁶⁷ In these situations, suppression of the analytes leads to too low concentrations. Errors in the results caused by ion suppression are sample-dependent and incidental, and quantitation becomes unreliable. However, the standard addition procedure in calibration would diminish the problem, but this is not possible during screening. It also requires substantial amounts of sample, which is often a limitation in forensic cases. Therefore, in applications for biological matrices, thorough validation should contain spike tests for a wide variety of authentic samples, including high and low spike levels to estimate the extent of suppression. In several applications for combinatorial chemistry, fast chromatography (“high throughput”) has been suggested, but this includes the obvious risk of ion suppression, which has been demonstrated to appear mostly during the LC-front peak. Therefore, using an efficient LC gradient reduces suppression by separating the analytes from the LC-front peak and from other matrix-related peaks, which may cause suppression later during the run.⁶⁹

3. AIMS OF THE STUDY

The purpose of the present study was to develop library search-based LC–MS techniques for drug screening and confirmation in forensic toxicology. The specific aims were the following:

- to create LC–MS/in-source CID and LC–MS/MS spectral libraries for toxicologically relevant drugs (I)
- to test the suitability of different modes of operation for screening and confirmation of drugs from urine samples, using β -blocking drugs as a sample drug group (I)
- to combine screening and quantification of drugs in blood in a simultaneous and automated procedure, using antihistamines as a sample drug group (II)
- to evaluate the long-term reproducibility of MS/MS product ion spectra and to investigate the universal applicability of MS/MS spectral libraries obtained with the same and with different manufacturers' triple-quadrupole instruments (III)
- to develop a broad-scale MRM screening method for drugs in blood samples (IV)
- to investigate a screening approach for drugs and their metabolites in urine by accurate mass without the use of reference compounds (V)

4. EXPERIMENTAL

Only the major experimental features are described in this section. More detailed descriptions can be found in the original publications **I – V**.

4.1 Standards and reagents

The test substances obtained from various pharmaceutical companies were of pharmaceutical purity. All solvents were of HPLC grade. Acetonitrile and methanol were purchased from Rathburn (Walkerburn, UK), ammonium acetate (p.a.), formic acid (p.a.), dichloromethane, isopropanol and tris(hydroxymethyl)-aminomethane (Tris, p.a.) from Merck (Darmstadt, Germany), and butyl acetate from Aldrich (Steinheim, Germany). Purified water was generated with an Alpha-Q water purification system from Millipore (Bedford, MA, USA).

For comparison of LC–MS/MS product ion spectra, 30 test substances were selected based on their ability to produce several fragments at collision energies of 20, 35 or 50 eV. Amitriptyline was used for standardization of the MS/MS fragmentation conditions, due to its extensive fragmentation pattern at all three collision energy levels (**III**). Accurate mass calibration of the TOF instrument was performed with Jeffamine D-230[®] (**V**), which was obtained from Fluka (Buchs, Switzerland).

4.2 Samples

Bovine blood (**II**, **IV**) or urine from laboratory personnel (**I**, **V**) were used for standard spikes. Authentic autopsy samples were used for testing the applicability of methods, e.g. sample behaviour during extraction steps, matrix effects and repeatability.

4.3 Instrumentation

LC separation was carried out with Perkin-Elmer Series 200 LC–MS pumps and autosampler using a vacuum degasser (**I**, **II**, **IV**). A Genesis C₁₈ column (100 mm x 2.1 mm i.d., particle size 4 µm; Jones Chromatography, Hengoed, UK) was used for separation, and a Purospher RP-18 LiChroCart 4-4 (40 mm, particle size 4 µm; Merck) was employed as a guard column. LC separation in the LC–MS/TOF

experiments was performed with an Agilent HP1100 binary pump system and autosampler, equipped with a 10-port switching valve for introducing the calibration standard (V). The separation column was a Luna C₁₈ (50 x 2.0 mm i.d., particle size 5 µm; Phenomenex, Torrance, CA, USA).

Mass spectrometry was performed using a PE Sciex API 365 triple stage quadrupole instrument (MSD-Sciex; Concord, ON, Canada) equipped with a PE Sciex Turbo Ion Spray ion source (I, II, IV). Three other triple quadrupoles were also used in the mass spectral library comparisons; one was an identical API 365 from Sciex and the other two were both Micromass Quattro triple quadrupoles (Manchester, UK) equipped with ion spray interfaces (III). Mariner API-TOF mass spectrometer (Applied Biosystems, Framingham, MA, USA) equipped with a PE Sciex Turbo Ion Spray interface was used (V) in the LC-MS/TOF measurements.

4.4 Methods

4.4.1 Extraction

Diverse extraction methods were used for the urine and blood samples. The urine samples were extracted using SPE with C₁₈ mixed-mode separation columns (Isolute Confirm HXC mixed mode, International Sorbent Technology (IST), Hengoed, UK). For blood samples, two-step LLE was used in which the basic drugs were first extracted at pH 11 with butyl acetate, followed by a second extraction of the acidic compounds at pH 3 with dichloromethane:isopropanol (95:5). Finally, the two extracts were combined prior to LC separation. Detailed descriptions for SPE and LLE are given elsewhere (I, II).

4.4.2 Liquid chromatography

In all studies, chromatographic separation was performed using a gradient run. The mobile phase consisted of acetonitrile as the organic solvent and an aqueous solution of ammonium acetate (10 mmol, 0.1% formic acid, pH 3.2) as a buffer, and the total flow was 200 µl/min. In studies in which only a limited number of compounds (16 (I) and 18 (II)) were analysed, the gradient was adjusted to resolve most of the compounds from each other.

Separation of all components was not possible in screening methods in which hundreds of different compounds were analysed, and the main objects were to obtain reasonable retention and as good a peak shape as possible for all compounds (**IV**, **V**). As a compromise, the following linear gradient was used with the Genesis C₁₈ column: CH₃CN from 20% to 100% in 10 min with a flow rate of 200 µl/min (**IV**). The total run time was 18 min including a 5-min equilibrium time at the beginning and 3 min for cleaning of the column with 100% CH₃CN at the end. The gradient was also linear with the Luna C₁₈ column, and the CH₃CN level rose from 5% to 95% in 10 min, but with a flow rate of 400 µl/min (**V**).

4.4.3 Mass spectrometry

MS was used in **I** and **V**, and MS/MS in **II**, **III**, and **IV**. In the MS/MS mode, a protonated molecule was selected as the precursor ion. For the halogenated compounds, the most abundant isotope (the monoisotopic mass) was selected. All mass spectrometric experiments were performed only in the positive ionization mode.

SIM was used for prescreening of β -blocking drugs (**I**). The declustering potential (orifice) was set at 40 V, and the protonated molecules $[M+H]^+$ were monitored with dwell times of 250 ms. Any matches to previously defined RTs and masses of the β -blocking drugs were then subjected to confirmation analyses in an automatic data-dependent experiment (DDE). Confirmation was performed in an automatic library search of the resulting product ion spectra against a previously created LC–MS/MS spectral library containing 400 compounds.

MRM was applied for prescreening and quantification of antihistamines (**II**); the ion transitions were monitored at a 200-ms dwell time. The MRM survey scan was automatically followed by a confirmation analysis that was initiated with DDE in a manner similar to that used in the method for β -blocking drugs. Identification was based on the LC–MS/MS product ion spectra obtained at a collision energy of 35 eV and searched against the MS/MS spectral library (**II**).

In the multicomponent screening method for drugs in blood (**IV**), all 238 transitions were monitored during a single chromatographic time period, but in three consecutive experiments with different collision energies (20, 35 and 50 eV). The appropriate collision energy and monitored ions were individually selected for all compounds to achieve the best obtainable specificity and sensitivity. However, the choice of collision energy was limited to 20, 35 or 50 eV, because the MS/MS spectral

library was created using these values. The shortest reasonable dwell time (25 ms) and total cycle time (6 s) were used. The positive result was based on correct precursor ion, specific fragment ion and RT of the analyte.

LC–MS/TOF was used in the broad screening of drugs from urine samples (V). Resolution (at least 5000) and mass accuracy (5 ppm) were optimized daily with three masses of the polymeric material Jeffamine D-230[®]. Jeffamine was also used for exact mass calibration of each sample by injecting it through a switching valve just before each sample injection. The entire mass spectrum from m/z 100–750 was acquired and stored with acquisition time of 2 s per spectrum. The compounds were identified without reference compounds by comparing the accurate mass of the peaks with the previously compiled list of exact masses of toxicologically interesting compounds and their metabolites and also by the metabolic pattern found in the urine samples.

Studies of long-term reproducibility of LC–MS/MS product ion spectra and compatibility of spectra obtained with different manufacturers' instruments (III) were performed by acquiring product ion spectra of 30 test substances at low (20 or 15 eV), medium (35 or 30 eV) and high (50 or 45 eV) collision energies, depending on the instrument. Standardization of the fragmentation conditions (collision energy and collision gas pressure) of different instruments was performed by visual comparison of the spectra obtained for amitriptyline, which produced extensive fragmentation patterns at all three collision energy levels.

5. RESULTS

5.1 Automated screening and confirmation

In routine forensic analysis, all positive findings from screening procedures must be confirmed. With quadrupole mass spectrometers, this can be based on library searching of LC–MS/in-source CID or LC–MS/MS spectra. This presumes the existence of spectral libraries, although no commercial libraries are currently available for LC–MS spectra. Therefore, two in-house libraries were created, for LC–MS/in-source CID and LC–MS/MS spectra, each containing 400 compounds (**I**). The in-source CID spectra were acquired by switching between low (25 V) and high (90 V) orifice voltages, and these two spectra were summed. While the low-voltage spectrum was dominated by the protonated molecule $[M+H]^+$ and the high-voltage spectrum by fragment ions, their summed spectrum was very informative. The LC–MS/MS product ion spectra were obtained at three different collision energies (20, 35 and 50 eV). For many compounds, spectra obtained with 20 eV contained only the protonated molecule, and even though it was very intensive the spectrum was not specific enough for identification. On the other hand, at 50 eV many compounds were too extensively fragmented and contained many small fragments at low intensity, and these spectra likewise were not suitable for identification. Therefore, the 35-eV spectra were added to the library of all compounds, as were the 20-eV or 50-eV spectra for those compounds for which the 35-eV spectra did not contain enough fragments at adequate intensity. The LC–MS/MS spectral library thus contains approximately 530 spectra. The difference between in-source CID and MS/MS spectra is demonstrated in **Figure 8**. The MS/MS spectra were more reliable in cases of co-eluting compounds, because co-elution resulted in mixed spectra that were not recognized in the LC–MS/in-source CID spectral library.

A fully automatic screening and confirmation procedure was developed for 16 β -blocking drugs in urine samples (**I**). SPE followed by a 2-step gradient run was used for extraction and chromatographic separation. The survey scan was performed using LC/MS/SIM, and a positive result was based on the correct protonated molecule and RT. The confirmation step was carried out in an automatic second injection during which the product ion spectra for all findings were acquired in the MS/MS mode. An application program was used to create the acquisition methods for the confirmation run. This program automatically split the chromatographic run into time periods corresponding to the RTs of the findings. A maximum of five product ion spectra were monitored during the same time period, otherwise a third injection was done for the other compounds appearing at the same time window; this procedure ensured

sufficient sensitivity. The spectra obtained were then automatically searched against the in-house spectral library, and the search results were also reported automatically. The method developed was




Figure 8. Comparison of the mass spectra for propranolol. Upper trace: LC–MS/in-source CID spectra (summed spectra acquired at 25- and 90-V orifice voltages). Lower traces: LC–MS/MS spectra at three collision energy levels.

sufficiently sensitive to identify β -blocking drugs in urine at the levels expected after therapeutic doses, except for pindolol, for which the limit of identification (LOI) based on the product ion spectra (1.2 mg/l) remained 10 times higher than the therapeutic range in blood (0.02 – 0.15 mg/l). Application of DDE for automation of the screening and confirmation procedure, from the start of the sample batch to the summary report of the library search results, was the main target of the study. In this method, automation was carried out with an Apple Scripting application program (Auto MS/MS Builder, Perkin-Elmer Sciex).

Another application of the DDE was developed for screening and quantitation of 18 antihistamines from blood (**II**). LLE was applied because whole-blood samples may cause blockage of SPE columns. The antihistamines are a group of chemically different compounds, and therefore both basic and acidic extraction steps were included. Mass spectrometric analysis was performed using MRM for the survey scan, and any matches to a previously defined list of RTs, protonated molecules and major fragment

ions were confirmed using product ion spectra in an automatically initiated second run. Quantitation was based on the MRM data obtained during the survey scan.

The extraction recovery varied widely between compounds: for basic drugs from 43% to 137%, and for acidic drugs from 23% to 66%. However, the recovery percentage itself is not essential, but in practical work good repeatability and high sensitivity are. For all antihistamines, the intra-assay precision varied from 3% to 9%, and the limits of quantification (LOQs) were between 0.0005 and 0.01 mg/l, far below the average maximum concentrations occurring after therapeutic doses of these drugs. The results indicated that the method is sufficiently reproducible and sensitive to be used for quantitation of antihistamines. Identification by product ion spectra was included in the method by DDE and the automatic library search application script. The identity of a drug was considered confirmed when the spectral fit was 70% or higher. The LOIs were not as low as the LOQs (mainly between 0.001 and 0.07 mg/l), but were low enough to confirm the drugs at higher therapeutic ranges in blood, except for clemastine. The validation results of the method are summarized in **Table 2**. Inaccuracy was expressed as the maximum bias of the results when two persons performed the analysis on different days during a single week.

Table 2. Validation data for the identification and quantitation of antihistamine drugs in blood samples using LC–MS/MS. LOQ = limit of quantitation, LOI = limit of identification

Compound	LOQ, mg/l by MRM	LOI, mg/l by MS/MS spectra	Precision %	Inaccuracy %	Recovery %
Acrivastine	0.001	0.005	7	29	35
Astemizole	0.002	0.001	3	20	39
Brompheniramin	0.0005	0.007	3	12	43
Carbinoxamine	0.002	0.002	3	6	37
Cetirizine	0.001	0.005	9	35	24
Chlorpheniramin	0.001	0.002	3	8	38
Cinnarizine	0.005	0.003	6	16	85
Clemastine	0.0005	0.015	6	15	91
Cyclizine	0.005	0.005	5	5	137
Diphenhydramin	0.005	0.015	4	12	65
Ebastine	0.01	0.001	5	20	62
Fexofenadine	0.0005	0.005	8	15	NE
Hydroxyzine	0.001	0.001	3	8	53
Levocabastine	0.0005	0.003	6	39	66
Loratadine	0.002	0.001	3	10	91
Mizolastine	0.002	0.002	3	10	43
Prometazin	0.008	0.007	3	8	32
Terfenadine	0.003	0.001	7	12	65

NE = not examined

5.2 Quantitative analysis

The calibration curves of the antihistamines were nonlinear along a broad concentration range. Various regressions for the same calibration points were tested, and the effect on correlation is illustrated in **Figures 9-11 (VI)**. The best accuracy was achieved for low concentration points by excluding the highest calibration points and using linear regression forced through zero (**Figure 10**). Quadratic regression including all calibration points was applied only when a broad concentration range was needed (**Figure 10**).




Figure 9. Linear calibration curve of carbinoxamine at concentration range 0.001-0.1 mg/l. Correlation coefficient = 0.9847.




Figure 10. Linear calibration curve of carbinoxamine at concentration range 0.001-0.1 mg/l. The highest calibration point is excluded and the curve is forced through zero. Correlation coefficient = 0.9993.




Figure 11. Quadratic calibration curve of carbinoxamine at concentration range 0.001-0.1 mg/l. Correlation coefficient = 0.9996.

Bending of the calibration curves was assumed to be due to ion suppression caused by high concentration of the analytes or by the matrix. Therefore, the possible presence of matrix-related ion suppression was estimated by spiking the antihistamines to authentic autopsy blood samples, including decayed and lumpy samples. Comparison of the relative standard deviation (RSD) within and between samples showed that the difference was only approximately 10% (**Table 3**).

Table 3. Estimation of ion suppression effect by calculating relative standard deviation (RSD) within and between 15 authentic autopsy samples spiked with 0.025 and 0.05 mg/l antihistamine mixture.

Compound	RSD-%	
	Within sample n = 15	Between samples n = 15
Acrivastine	8.9	12.9
Astemizol	11.9	22.6
Bromopheniramine	4.4	10.7
Carbinoxamine	3.3	9.5
Cetirizine	9.0	19.0
Cinnarizine	19.1	37.6
Clemastine	18.8	22.2
Chlorpheniramine	3.6	9.4
Cyclizine	10.9	20.9
Diphenhydramine	10.2	24.9
Ebastine	13.6	28.2
Hydroxyzine	7.1	24.1
Levocabastine	18.2	25.2
Loratadine	13.0	23.6
Mizolastine	8.8	25.8
Prometazine	10.6	21.6
Terfenadine	16.5	21.9

Therefore, it was concluded that the nonlinearity of the calibration curves at high concentrations in our study was not caused by the matrix, but by too high a spiking concentration. In such circumstances, the dynamic range ends and part of the analyte ions remain inside the droplets and will not get into the gas phase.

5.3 Reproducibility of MS/MS spectral library search

The LC–MS/MS product ion spectra of 30 test substances were acquired using three different collision energy levels, and searched against the in-house library containing 400 compounds that was created

four years earlier. Very good Fit percentages (86-98%) were obtained for the newly acquired spectra of all compounds at all tested fragmentation conditions, demonstrating good long-term reproducibility.

To examine the interlaboratory reproducibility, comparison of spectra between two similar instruments from the same manufacturer was carried out. The libraries were independently created and both contained spectra of approximately 400 drugs. In these libraries, the spectra were acquired at three or four collision energy levels, two of which were the same (20 eV and 50 eV), and could be compared directly. Thirty test substances were selected from one library and searched against the other. The Fit percentages varied between 93% and 95%. At medium energy, one library had spectra at 35 eV and the other at 30 and 40 eV. Comparison showed that the spectra at 35 eV were closer to those at 30 eV than at 40 eV. Even though the collision energies were not exactly the same, Fit percentages were as good as 82–89%.

To examine the reproducibility of spectra acquired with different manufacturers' triple-quadrupole instruments, standardization of fragmentation conditions was needed prior to spectral comparison. Amitriptyline was suitable for this purpose, because it produced product ion spectra with several fragments at all applied CEs. After standardization, 30 test substances were acquired with two instruments from two manufacturers, and the product ion spectra obtained were searched against the reference library. A graphic presentation of the results is shown in **Figure 12**.




Figure 12. Comparison of spectra obtained with different manufacturers' triple quadrupoles. Similarity is expressed as Fit percentage against the reference library of the Sciex A instrument.

As can be seen, the similarity of spectra obtained with different manufacturers' instruments, was generally very good (Fit between 80% and 85%). The only obtrusively low value for dipyridamole (45%) was regarded as random error occurring during handling or processing of the sample, because no special difficulties have been encountered during previous use of this compound.

5.4 Comprehensive screening by multiple-reaction monitoring

A comprehensive screening for drugs in blood was developed for LC–MS/MS operating in the MRM mode. This approach was successfully enlarged to include 238 drugs. It was demonstrated that as short a dwell time as 25 ms was sufficient to obtain an adequate signal-to-noise ratio for reliable detection of compounds at their therapeutic levels. The short dwell time enabled monitoring of a large number of compounds during a single chromatographic run without splitting it into time periods. Positive identification was based on three criteria: correct precursor ion, fragment ion and RT. Additionally, the signal-to-noise ratio at the limit of detection (LOD) was required to be at least three, data points across the chromatographic peak at least four and areas for internal standards above the limits given to show that extraction was successful. The LOD values were determined for all 238 drugs and were within the therapeutic ranges of these drugs (**Table 4**), including such acidic/neutral compounds (e.g. paracetamol and theophylline) that are not very sensitive in positive ion mode.

The suitability and coverage of the method can be seen from **Table 4**, which presents typical therapeutic ranges, LODs, RTs, monitored fragment ions and collision energies for 80 drugs commonly found in autopsy cases in Finland between 2000 and 2003. Screening for only these compounds would cover 87% of all findings obtained with all other methods during these years (GC, GC–MS, TLC and OPLC). Comparison of 71 authentic autopsy blood samples revealed that 92% of the findings were consistent with those obtained with GC, GC–MS or TLC/OPLC. Of a total of 256 positive findings, only 18 could not be verified by any other method or from other sample material. The explanation for these findings remains obscure; however, none of the other methods contained the same compounds or was as sensitive as MRM.

5.5 Comprehensive screening by accurate mass measurement

To be able to identify even those compounds for which primary reference standards are not readily available, a screening approach based on accurate mass measurement was developed. A method for

Table 4. Characteristics of the MRM screening method. Data for 80 drugs commonly found in Finland during 2000-2003. Therapeutic concentration ranges were collected from references 70-79.

Compound	Therap. conc. mg/l blood	LOD mg/l	RT min.	[M+H] ⁺	Fragment	CE eV
Caffeine	8 – 15	1.00	2.77	195.0	138.0	35
Temazepam	0.4 - 0.9	0.02	7.18	301.0	255.0	35
Oxazepam	0.1 - 1.4	0.02	6.33	287.0	269.0	20
Diazepam, desmet-	0.1 -1.7	0.05	7.18	271.0	208.0	35
Diazepam	0.1 - 2.5	0.02	8.08	285.0	222.0	35
Paracetamol	10 – 25	5.00	2.49	152.0	110.0	20
Citalopram	0.06 – 0.4	0.02	5.71	325.0	109.0	35
Nicotine	0.01 - 0.04	0.05	2.15	163.2	132.0	20
Zopiclone	ad 0.1	0.10	3.96	389.0	245.0	20
Codeine	0.03 – 0.1	0.10	2.54	300.2	215.0	35
Levomepromazine	0.05 - 0.14	0.02	6.50	329.0	247.0	35
Carbamazepine	5 – 10	0.02	6.10	237.0	194.0	20
Lidocaine	2 – 5	0.05	3.73	235.2	86.0	20
Mirtazapine	(ad 0.2)	0.02	4.35	266.2	195.0	35
Amitriptyline	0.04 - 0.2	0.02	6.56	278.0	233.0	20
Tramadol	ad 0.6	0.02	4.18	264.0	58.0	20
Chlordiazepoxide	1- 3	0.02	5.71	300.2	282.0	35
Demoxepam		0.02	5.82	287.0	269.0	35
Morphine	0.08 - 0.12	0.10	1.97	286.0	201.0	35
Citalopram, desmet-		0.02	5.53	311.2	262.0	20
Metoprolol	0.1 - 0.6	0.02	4.07	268.2	191.0	20
Promazine	0.1 - 0.4	0.02	6.22	285.0	86.0	20
Doxepine	0.03 - 0.15	0.02	5.88	280.2	235.0	20
Nortriptyline	0.05 - 0.25	0.02	6.44	264.2	233.3	20
Fluoxetine	0.09 - 0.5	0.10	6.78	310.2	148.0	20
Chlorprothixene	0.04 - 0.3	0.02	6.95	316.0	231.0	35
Propranolol	0.03 - 0.25	0.02	5.37	260.2	155.0	35
Oxycone	0.01 - 0.1	0.05	2.83	316.2	298.3	20
Theophylline	8 – 20	5.00	2.37	181.2	124.2	20
Olanzapine	ad 0.2	0.05	2.99	313.2	256.0	35
Warfarin	1.0 - 3.0	0.02	7.90	309.2	251.0	20
Trimethoprim	1.5 - 2.5	0.05	3.11	291.2	230.0	35
Thioridazine	0.2 - 1.0	0.02	7.51	371.0	126.0	35
Diltiazem	0.05 - 0.3	0.02	5.82	415.0	178.0	35
Venlafaxine	0.07 - 0.3	0.02	4.86	278.2	260.3	20
Lorazepam	0.05 - 0.24	0.02	6.56	321.2	303.0	20
Phenytoin	10 – 20	0.05	6.10	253.2	182.3	20
Alprazolam	0.01 - 0.02	0.02	6.05	325.2	297.0	35
Mianserine	0.03 - 0.12	0.02	5.65	265.2	208.0	20
Dextropropoxyphen	0.1 - 0.75	0.05	6.56	340.0	266.0	20

Table 4 (cont.). Characteristics of the MRM screening method. Data for 80 drugs commonly found in Finland during 2000-2003. Therapeutic concentration ranges were collected from references 70-79.

Compound	Therap. conc mg/l blood	LOD mg/l	RT min.	[M+H] ⁺	Fragment	CE eV
Metoclopramide	0.04 - 0.1	0.02	3.84	300.2	227.0	20
Atenolol	0.2 - 0.6	0.30	1.70	267.2	225.0	20
Clozapine	0.1 - 1.0	0.02	5.59	327.2	270.3	35
Ketoprofen	6.0 – 14	0.10	7.28	255.0	209.0	35
Risperidone	0.004 - 0.027	0.02	4.90	411.2	191.0	35
Chlorpromazine	0.05 - 0.3	0.02	6.95	319.0	246.0	35
Verapamil	0.07 - 0.35	0.02	6.50	455.2	165.0	35
Orphenadrine	0.03 - 0.85	0.02	6.10	270.4	181.2	20
Trimipramine	0.01 - 0.3	0.02	6.67	295.2	100.0	20
Carbamazepine, 10-OH	2 – 30	0.10	4.52	255.2	237.0	20
Amiloride	approx. 0.04	0.10	2.03	230.2	171.0	20
Perphenazine	0.0004 – 0.03	0.00	6.93	404.2	171.3	35
Buprenorphine	0.5 - 10 µg/l	0.01	5.87	468.2	396.3	50
Sertraline	0.05 - 0.25	0.02	6.78	306.0	275.2	20
Quinine	2-8	0.02	4.24	325.2	307.0	35
Oxcarbazepine	< 1	0.02	5.31	253.2	236.0	20
Melperone	0.04 - 0.06	0.02	5.03	264.0	165.0	35
Moclobemide	1.5 - 2.5	0.05	3.73	269.2	182.0	20
Triamteren	0.01 - 0.2	0.10	3.22	253.8	237.0	35
Ranitidine	0.15 - 0.25	0.10	1.80	315.2	176.0	20
Bisoprolol	0.01 - 0.1	0.02	4.97	326.2	116.0	20
Tetrahydrocannabinol		0.05	12.25	315.2	193.2	20
Indomethacine	0.7 – 4	0.05	8.58	358.0	138.8	20
Sotalol	0.5 – 4	0.10	2.13	273.2	255.0	20
Morphine, 6-monoacetyl-		0.10	2.65	328.2	211.0	35
Zolpidem	0.08 - 0.15	0.02	4.69	308.2	235.3	35
Lamotrigine	0.5 - 4.5	0.10	4.01	256.0	211.0	35
Hydroxyzine	0.05 - 0.1	0.02	6.27	375.2	201.0	35
Midazolam	0.08 - 0.2	0.02	5.93	326.0	291.0	35
Paroxetine	0.008 - 0.05	0.02	6.15	330.2	192.0	35
Fluvoxamine	0.05 - 0.25	0.02	6.33	319.2	259.0	20
Hydroxychloroquine	0.1 - 1.0	<0.3	2.43	336.2	247.0	35
Aminophenazone, 4-met-	approx. 10	5.00	2.60	218.2	187.0	20
Clonazepam, 7-amino-		0.02	4.35	286.2	222.0	35
MDMA		0.02	3.28	194.2	163.0	20
Chloroquine	0.02 - 0.5	0.02	2.65	320.0	247.0	35
Midazolam, 1-hydroxy-		0.02	6.16	347.2	324.0	35
Mesoridazine	0.2 - 1.6	0.02	5.37	387.2	372.3	35
Amiodarone	0.8 - 2.8	0.05	10.22	646.0	100.3	35
Sulpride	0.03 - 0.6	0.10	1.85	347.2	214.0	35

433 drugs and metabolites in urine was developed with LC–MS/TOF (**V**). The mass accuracy of 5 - 10 ppm was obtained for the majority of these drugs in authentic samples, using internal mass calibration with each sample. The major effort in this study was to develop postrun software to search for the selected masses in the total ion chromatogram (TIC), acquired as a full mass spectrum from m/z 100-750. For this purpose, a list of the 433 drugs selected was stored, containing the theoretical monoisotopic mass, RT (if known), compound name and formula, and a compound code. Using a preselected mass window, this list was used for automatic generation of extracted ion chromatograms from the spectrum acquired, and to arrange the results so that the parent drug and its metabolites were reported together, which made interpretation of the results easier. **Table 5** presents an example of the automatic report of the results (see details in **V**). Comparison of this screening method with the established TLC and GC methods with authentic urine samples indicated good agreement.

Table 5. An example of a screening report of the results obtained with the LC–MS/TOF screening method.

Code*	Compound**	Mass Found	Reference Mass	Ppm Error	Retention Time	Reference Retention Time***	Retention Time Error	Peak Area
<u>0153</u>	<u>DEMOXEPAM</u>	<u>287.0584</u>	<u>287.0582</u>	<u>-0.6</u>	<u>6.53</u>	<u>6.6</u>	<u>-0.07</u>	<u>8753</u>
<u>0154.1347</u>	<u>NORDIAZEPAM</u>	<u>271.0641</u>	<u>271.0633</u>	<u>-3</u>	<u>6.96</u>	<u>6.9</u>	<u>0.06</u>	<u>1968</u>
<u>0155.1344.2822</u>	<u>OXAZEPAM</u>	<u>287.0584</u>	<u>287.0582</u>	<u>-0.6</u>	<u>6.53</u>	<u>6.9</u>	<u>-0.37</u>	<u>8753</u>
0471	FLUOXETINE	310.141	310.1408	-0.6	6.46	6.4	0.06	6836
0847	PROMAZINE							
	SULFOXIDE	301.1398	301.1369	-9.5	10.44	0		547
	O-DEMETHYL							
	DEACETYL							
1666	NORDILTIAZEM	345.1223	345.1267	12.8	0.46	0		562
	O-DEMETHYL							
	DEACETYL							
1666	NORDILTIAZEM	345.1227	345.1267	11.7	4.57	0		30779
1831	CODEINE	300.1601	300.1598	-1	4.89	1.3	3.59	1394
2141	PROPRANOLOL	260.162	260.1647	10.6	5.50	0		20129
	10-OH-							
2255	NORTRIPTYLINE	280.1714	280.1696	-6.4	5.67	6	-0.33	474080
<u>2431</u>	<u>DOXEPIN</u>	<u>280.1714</u>	<u>280.1696</u>	<u>-6.3</u>	<u>5.67</u>	<u>5.7</u>	<u>-0.03</u>	<u>474080</u>
<u>2432</u>	<u>NORDOXEPIN</u>	<u>266.1536</u>	<u>266.1539</u>	<u>1.1</u>	<u>5.07</u>	<u>5.6</u>	<u>-0.53</u>	<u>2646</u>
<u>2432</u>	<u>NORDOXEPIN</u>	<u>266.1547</u>	<u>266.1539</u>	<u>-2.9</u>	<u>5.60</u>	<u>5.6</u>	<u>0</u>	<u>288347</u>
<u>2433</u>	<u>DOXEPIN-N-OXIDE</u>	<u>296.1633</u>	<u>296.1645</u>	<u>4.1</u>	<u>5.18</u>	<u>5.2</u>	<u>-0.02</u>	<u>39720</u>
<u>2433</u>	<u>DOXEPIN-N-OXIDE</u>	<u>296.1639</u>	<u>296.1645</u>	<u>2</u>	<u>5.96</u>	<u>5.2</u>	<u>0.76</u>	<u>101014</u>
<u>2731</u>	<u>ZOPICLONE</u>	<u>389.111</u>	<u>389.1127</u>	<u>4.2</u>	<u>0.46</u>	<u>4.6</u>	<u>-4.14</u>	<u>983</u>
<u>2731</u>	<u>ZOPICLONE</u>	<u>389.1105</u>	<u>389.1127</u>	<u>5.6</u>	<u>4.57</u>	<u>4.6</u>	<u>-0.03</u>	<u>50133</u>
<u>2732</u>	<u>NORZOPICLONE</u>	<u>375.0964</u>	<u>375.0967</u>	<u>0.8</u>	<u>0.46</u>	<u>4.5</u>	<u>-4.04</u>	<u>678</u>
<u>2732</u>	<u>NORZOPICLONE</u>	<u>375.0981</u>	<u>375.0967</u>	<u>-3.9</u>	<u>4.50</u>	<u>4.5</u>	<u>0</u>	<u>9075</u>
	<u>ZOPICLONE-</u>							
<u>2733</u>	<u>N-OXIDE</u>	<u>405.1069</u>	<u>405.1073</u>	<u>0.9</u>	<u>4.89</u>	<u>4.9</u>	<u>-0.01</u>	<u>8774</u>
2931	HYDROCODONE	300.1601	300.1598	-1	4.89	3.1	1.79	1394
3021	NALORPHINE	312.1572	312.1596	7.5	5.35	0		9631
3131	ETHYLMORPHINE	314.1749	314.1746	-0.8	4.96	0		3858
3131	ETHYLMORPHINE	314.1686	314.1746	19.4	5.32	0		856
3441	REMOXIPRIDE	371.1008	371.0961	-12.6	11.47	0		556
3822	NORCLOBAZAM	287.0584	287.0582	-0.6	6.53	0		8753

* Compound Code xxyz: xx = parent drug group, y = number of compounds in the group, z = ordinal number of the drug in the group

** Correct findings underlined

*** For those compounds without a RT in the library, a value of 0 was given.

6. DISCUSSION

In the present study, the scope of LC–MS was widened from target analysis to comprehensive screening and confirmation utilizing a library search. In forensic toxicology, however, extraction of drugs from biological material is a critical step related to comprehensiveness. Other issues that may limit the coverage of a screening method are chromatography, ionization, prescreening strategy, sensitivity and reliability of identification.

Relatively good separation is needed even when MS/MS is used for detection. Separation of analytes from each other and from the biological material reduces the probability of ion suppression in an ES ion source. RT time was also seen to be very useful as one criterion for identification of unknowns in the methods developed (**I**, **II**, **IV**). Detailed optimization of LC conditions and eluent composition was not regarded as necessary, since several studies showed that LC composition does not affect the appearance of MS/MS spectra.^{29-31,33,34} Therefore, attention was focused only on separation of analytes from the LC-front peak and on obtaining a reasonable compromise of total analysis time, reasonable peak shape and separation. Separation of all analytes would probably not have been even possible in methods containing several hundreds of compounds, and therefore we attempted to use LC procedures as simple and general as possible. Keeping these practical aspects in mind, we chose a commonly used column (RP C-18), solvent (acetonitrile) and buffer (ammonium acetate), and used a simple linear gradient (acetonitrile from 20% to 100% in 10 min). The total flow was maintained at 200 μ l/min to ensure evaporation of the eluent throughout the gradient. Otherwise, the analytes would have remained inside the droplets and exited the ion source through the exhaust outlet, thereby decreasing the sensitivity. As was seen in the MRM screening of 238 drugs (**IV**), sufficient separation was achieved under these general LC conditions, and the analytes were eluted quite evenly along the gradient.

For the survey scan, both the SIM and MRM modes were tested and found suitable (**I**). In the SIM mode, all compounds having the same m/z value passed the survey scan and therefore more precursor ions were included in the following confirmation step than in the MRM mode, in which the fragment ions were also defined in advance. Preselection of the precursor and fragment ions limits the coverage of the survey scan, but on the other hand makes the survey scan much more selective and sensitive than using the full scan. As a new point of view, it could be possible to perform the survey scan with a step size of 1.0 Da instead of the commonly used 0.1 Da, and thereby select all total mass values within the mass range of interest, e.g. m/z 150-700 for toxicologically relevant drugs and by that means cover the entire mass range. This approach has not been studied in practice, but it could be as “general” as using

a full scan for the screening step⁴⁴ and probably would be more sensitive. Whatever survey scan is used, the confirmation step should be based on product ion spectra searched against a spectral library. For β -blocking drugs, the survey scan with SIM was selected due to its simplicity, whereas MRM provided the simultaneous quantitation needed in the antihistamine analysis. Currently however, MRM is applied to all LC-MS screening and quantitation analyses, due to its better selectivity and sensitivity. The methods for antihistamine and β -blocking drugs are in routine use with the exception that the confirmation step could not yet be automated after the change in software from the MacIntosh-based Multiview 1.4 to MS Windows-based Analyst 1.3.

Triple-quadrupole mass spectrometers have widely been used for quantitative analysis because of their high selectivity and sensitivity combined with good reproducibility. The special challenge for quantitation of drugs in forensic samples is that the difference between low therapeutic and lethal concentrations can be as much as 1000-fold. During validation of the antihistamine method (II), it was noted that the calibration curves were not linear over a very broad range of concentrations (0.05-500 $\mu\text{g/l}$). This is typically encountered in quantitation with LC-MS/MS/MRM and was also reported by others.⁵⁹ Therefore, the calibration points and regression were chosen according to relevant concentration ranges. Bending of the calibration curves was first suspected to be due to ion suppression caused by the matrix, which was claimed to be a serious problem in LC-MS for quantitation of drugs in forensic samples where the matrix varies remarkably from one sample to another.⁸⁰ However, our spiking tests of antihistamines in several autopsy samples revealed only slightly higher RSDs between samples than within samples, which in our opinion showed that matrix-related ion suppression did not affect this analysis. However, the limited dynamic range was more likely due to suppression of the analyte itself in high concentrations. Our observations were in agreement with other ion-suppression studies,^{69,81} which demonstrated that matrix-related ion suppression is more pronounced in the LC-front peak than in the rest of the gradient, where the analytes are separated from the polar and unretained components of the matrix.

Various strategies for combined screening and confirmation of drugs were examined: single-MS using SIM for the survey scan and in-source CID spectra or MS/MS product ion spectra for confirmation, MS/MS using MRM for the survey scan and MS/MS product ion spectra for confirmation, and LC-MS/TOF using accurate masses for the survey scan and confirmation. The single quadrupole instrument is a suitable and nonexpensive choice for screening. Moreover, the LC-MS/in-source CID spectra, being summed low- (+25 V) and high-orifice voltage (+90 V) spectra, contained both fragment

ions and an intensive protonated molecule, which was usually weak or totally missing from the LC–MS/MS product ion spectra at medium or high collision energy levels. Various combinations of low and high voltages were used by others, e.g. +20, +50 and +80 V,²⁹ ± 20 V and ± 80 V,³⁰ ± 10 V, ± 50 V and ± 100 V,³¹ or even linear ramping of the voltage,³³ but in general, for relevant information only two different levels are needed. The presence of the protonated molecule in the spectrum is an undeniable benefit against LC–MS/MS spectra, which were more specific because the only origin of the fragments was the precursor ion chosen. More harmony has been shown in the selection of collision energies in MS/MS. In addition to our choice of using 20, 35 or 50 eV, only a combination of 20, 30, 40 and 50 eV was applied.⁴⁰ We observed that still higher or lower collision energies added no new information to the product ion spectra. As can be concluded from the diversity of the applications, it is reasonable and indispensable to standardize the fragmentation conditions if library searches are commonly and routinely to be used for identification. In contrast, it is always beneficial to optimize relevant fragmentation conditions to obtain the highest sensitivity for quantitation purposes.

The possibility of creating and using universal LC–MS/MS spectral libraries was evaluated. Before universal LC–MS/in-source CID and LC–MS/MS spectral libraries can be created and used, agreement should be reached on the fragmentation conditions to be employed, but to date this has not been done, as previously discussed. To determine whether there is a basis at all to usage of spectral libraries, reproducibility of LC–MS/MS product ion spectra within one and between separate triple-quadrupole mass spectrometers was examined. Long-term reproducibility within instruments was excellent and in agreement with previous studies,⁴⁰ which encouraged further testing for similarity of spectra obtained with similar instruments from the same and from different manufacturers. The results showed that LC–MS/MS spectra, acquired with one instrument, can successfully be searched against a library created with another instrument of the same type. This is a promising finding for future efforts to develop generally available LC–MS/MS spectral libraries, and warrants further comparison with other instruments and manufacturers.

Comparison between spectra is difficult when instruments use different software programs that are not compatible. We also observed that algorithms for data processing prior to the library search were not similar and altered the data in different ways, leading to unacceptable library search results. For instance, one software used centroiding parameters that deleted important small peaks, such as those for the protonated molecules. During the library search process itself, the intensity factor was also seen to affect the search results. In contrast to previous opinions,^{30,35} judgment on similarity should include tight criteria for peak intensity ratios, at least when conclusions are drawn on the performance of

instruments. Mass spectra are generally used for identification of unknown compounds, and the criteria for positive identification have been discussed in many contexts. However, there still is no common agreement on the acceptance criteria for a reliable match, although suggestions of approximately 70-80% were presented for a fair or good match.^{33,34} According to studies on the subject and our previous experience with actual samples, we suggest that a Fit of approximately 70% or higher would result in a satisfactory confidence level, presuming that the peak intensity would allow the entire spectrum to be detected.

Comprehensive screening with MRM (**IV**) was also tested and was found to be sensitive and reliable for a large number of compounds. Some important factors demanded special attention: cross-talk, which may occur if two compounds co-elute and have the same fragment ions, instrument scanning speed, which limited the number of compounds that were detected during a single chromatographic run and dwell time, which effected sensitivity and also limited the number of compounds. Cross-talk is a known feature of older triple-quadrupole models, but can be avoided by careful planning of the order of MRM transitions, as was demonstrated earlier.⁵⁶ Scanning speed and the applied dwell time together contributed to the sensitivity. Increasing the dwell time to promote sensitivity led to fewer data points across the chromatographic peak and thereby made detection insecure. However, instrumental technology has improved rapidly, and at present dwell times as low as 5 ms can be used. According to the generally accepted rules for reliable identification,⁸² the number of MRM transitions should be at least two, providing a total of three diagnostic ions. With the additional criterion for RT, these parameters provide a high confidence level in both screening and quantitation. The method developed could easily have been expanded to also include confirmatory ions, but the available instrument scanning speed was decisive and determined the number of transitions that could be monitored during a single run. However, the method developed with 238 transitions is the broadest published screening application of MRM available.

One way to enlarge the coverage of the method is to split the chromatographic run into time windows, as was proposed for multicomponent screening with GC.⁵⁴ By this means, fewer transitions are monitored at the same time, and therefore higher dwell times can be used to improve sensitivity or the number of compounds searched can be increased. Sensitivity can also be improved by optimizing the collision energy for every compound individually.⁵⁹ Optimization was not performed for the 238 compounds in our method, because the intention was to use standard operating conditions in all LC-MS/MS work in the laboratory. Even so, the sensitivity obtained in the MRM screening method developed was sufficiently high for routine studies of forensic samples.

In the comprehensive screening method using LC–MS/TOF (V), no separate prescreening step was needed, while during acquisition the instrument recorded all masses at the selected mass range. Using this feature, TOF instruments enable a basically unlimited number of toxicants to be screened during a single injection without sacrificing the sensitivity or selectivity. One limitation, set by the user, was the selection of compounds on the target list, which was limited to 433 common drugs and their metabolites. Some complexity in interpretation of the results was also caused by the fact that two or even more drugs were obtained for the same molecular formula. The number of candidates differing by formula can be further decreased by using an instrument with higher mass accuracy, or using RT as an identification criterion. RTs were not used in the automatic procedure, because they were not known for most of the metabolites. However, the metabolic pattern was an efficient tool for ruling out apparent false-positive findings. Automatic processing was absolutely necessary in this method, because substantial information was extracted from huge amounts of data. Nonautomatic methods cannot be accepted for routine analysis when large numbers of samples are to be analysed daily. Automation also decreases the possibility of human errors. Special programs were also needed for the other methods developed, because the original software did not contain the necessary options for data handling and convenient reporting.

RTs of metabolites can be collected from routine samples containing parent drugs and their metabolites, and these data were later added to the identification criteria in the improved version of the method,⁸³ which has been taken into routine use and accredited by the Finnish Accreditation Service (FINAS) in June 2004. The possibility of detecting toxicants without reference compounds is a major advantage of this approach. In forensic toxicology, maintaining a large selection of reference compounds is very expensive and even impossible, because most of the metabolites are not commercially available. Therefore, LC–MS/TOF appears to be very suitable for this type of application, and this technique was considered as the closest approach to the so-called “general unknown screening”, especially if high-resolution instruments were used.

Both screening methods, LC-MS/MS/MRM (**IV**) and LC-MS/TOF (**V**), are suitable for routine use in forensic studies. Screening of real unknowns is not possible with the MRM technique, but from the practical point of view, the selection of compounds routinely found in post mortem forensic toxicological cases may not be very wide. For example, in the Forensic Toxicology Laboratory of the University of Helsinki between 2000 and 2003, approximately 90 of 300 compounds found covered 95% of all findings. Therefore, the choice of method can be done according to the instrumentation available and screening strategy preferred.

7. CONCLUSIONS

This dissertation described novel approaches for expanding the limits of LC–MS from conventional target analysis of a few compounds to comprehensive analysis based on large spectral libraries. The challenges originated from drug screening and confirmation problems encountered in forensic and clinical toxicology. The strengths of LC–MS over other techniques were the broad range of compounds that could be analysed and the ruggedness of instrumentation against difficult sample matrices.

Triple-quadrupole MS/MS proved to be a selective and sensitive technique for identification based on library searching of product ion spectra. Two automated procedures demonstrated the advantages of the technique. SIM and MRM were applied to the qualitative analysis of β -blocking drugs in urine and quantitative analysis of antihistamines in blood, respectively, with confirmation by product ion spectra against an in-house library of 400 drugs. The quantitation method of antihistamines also showed that with MRM techniques, compounds at very low concentration can be quantitated accurately from forensic samples containing high background.

The in-house library of product ion spectra of 400 drugs was shown to be reproducible in the long term. Moreover, spectral libraries created with identical instruments from the same manufacturer, were fully compatible. The finding that the spectra obtained using a different manufacturer's instruments under standardized conditions could also be successfully searched against the in-house library widens the prospect for the generation of universal spectral libraries. The future of LC-MS/MS libraries will be dependent not only on the activity of LC-MS/MS users but also on that of the manufacturers, who play an important role in developing the instrument software. To date, there has been little interest among manufacturers to develop or financially support work on universal LC-MS/MS spectral libraries; however, this may well change along with the novel studies.

The largest target-screening method published using MRM included transitions for 238 drugs, and the method was also amenable to simultaneous quantification. The LODs in blood were generally at therapeutic levels, suggesting the method was sufficiently sensitive for use in forensic contexts.

LC–MS/TOF provided a screening method for drugs and metabolites without reference standards, and a target database for 433 compounds was created. A mass accuracy of 20 ppm obtained in real urine

samples together with the metabolic pattern obtained were suggested to be sufficient to detect the correct findings and to rule out apparent false-positive findings, with the use of dedicated software.

The methods described persuaded us that LC-MS is very suitable for a variety of applications in forensic toxicology, in which high reliability of results is categorical. Screening of a wide variety of compounds and quantitation of a wide range of concentrations from a diverse matrix is a demanding task, but LC-MS proved to be amenable to such applications. However, no single technique alone is sufficient to attain the expected confidence level and therefore LC-MS, adequate as it is, cannot replace all other techniques, but will be used together with those recognized to be useful and effective.

ACKNOWLEDGEMENTS

This study was carried out at the Department of Forensic Medicine, University of Helsinki, during the years 1999-2004.

I especially acknowledge Prof. Erkki Vuori, Head of the Forensic Chemistry Division, for his firm support and his willingness to offer a stimulating environment and equipment for my studies. I also appreciate his encouraging comments and the great interest he has shown in my work during these years. I also recognize the importance of the support and encouragement offered by Prof. Reija Jokela, Professor of Organic Chemistry in the Helsinki University of Technology, not only during the process of this thesis but also during my previous studies at the University of Technology.

I am very grateful to my first supervisor Dr. John Robson, who initially guided my enthusiasm to work with LC-MS and provided his expertise for realizing the broad range of new ideas, and who also managed the cooperation with the instrument manufacturer. I also greatly appreciate my second supervisor Docent Ilkka Ojanperä for stimulating discussions and his patience in helping me to transform my tangled manuscripts into scientific articles. My special thanks to Pirjo Tiainen for her skilful laboratory assistance during the experimental work. The entire staff of the Laboratory of Forensic Toxicology deserves my warmest compliments by being most helpful and cooperative, and by providing educated guesses for solving a few of the so-called 'challenges'.

I also thank my good friends, who have been my cheerleaders, always encouraging me without second thoughts (even when they should have) in whatever I have done in my life - and especially in the last few months during those desperate moments when I was just about ready to give up on this thesis.

Finally, and most warmly, I thank my family for their never-ending belief in me.

Financial support from Consolidated Research Incorporated (Los Angeles, CA, USA) is gratefully acknowledged.

REFERENCES

1. Drummer, O.H., Chromatographic screening techniques in systematic toxicological analysis, *J. Chromatogr. B* 733 (1999) 27-45.
2. Poletti, A., Systematic toxicological analysis of drugs and poisons in biosamples by hyphenated chromatographic and spectroscopic techniques, *J. Chromatogr. B* 733 (1999) 47-63.
3. deZeeuw, R.A., Franke, J.P., "General unknown" analysis, in *Handbook of Analytical Separations*, ed. Smith, R.M., Elsevier, Amsterdam 2000, 567-599.
4. Cosbey, S.H., Craig, I., Gill, R., Novel solid-phase extraction strategy for the isolation of basic drugs from whole blood. Preliminary study using commercially available extraction cartridges, *J. Chromatogr. B: Biomedical Applications* 669 (1995) 229-235.
5. Yawney, J., Treacy, S., Hindmarsh, K.W., Burczynski, F.J., A general screening method for acidic, neutral, and basic drugs in whole blood using the Oasis MCX column, *J. Anal. Toxicol.* 26 (2002) 325-332.
6. Chen, X.-H., Franke, J.P., Wijsbeek, J., deZeeuw, R.A., Isolation of acidic, neutral and basic drugs from whole blood using a single mixed mode solid-phase extraction column, *J. Anal. Toxicol.* 16 (1992) 351-355.
7. Chen, X.H., Franke, J.P., Ensing, K., Wijsbeek, J., deZeeuw, R.A., Pitfalls and solutions in the development of a fully automated solid-phase extraction method for drug screening purposes in plasma and whole blood, *J. Anal. Toxicol.* 17 (1993) 471-476.
8. Chen, X.H., Franke, J.P., Ensing, K., deZeeuw, R.A., Study of lot-to-lot reproducibilities of Bond Elute Certify and Clean Screen DAU mixed-mode solid-phase extraction columns in the extraction of drugs from whole blood, *J. Chromatogr. B: Biomedical Applications* 617 (1993) 147-51.
9. Cox, R.A., Crifasi, J.A., Dickey, R.E., Ketzler, S.C., Pshak, G.L., A single-step extraction for screening whole blood for basic drugs by capillary GC/NPD, *J. Anal. Toxicol.* 13 (1989) 224-228.

10. Hoja, H., Marquet, P., Verneuil, B., Lotfi, H., Pénicaut, B., Lachâtre, G., Applications of liquid chromatography–mass spectrometry in analytical toxicology: A review, *J. Anal. Toxicol.* 21 (1997) 116–124.
11. Maurer, H.H., Liquid chromatography–mass spectrometry in forensic and clinical toxicology, *J. Chromatogr. B* 713 (1998) 3-25.
12. Marquet, P., Lachâtre, G., Liquid chromatography–mass spectrometry: potential in forensic and clinical toxicology, *J. Chromatogr. B* 733 (1999) 93-118.
13. Bogusz, M.J., Hyphenated liquid chromatographic techniques in forensic toxicology, *J. Chromatogr. B* 733 (1999) 65-91.
14. Van Bocxlaer, J.F., Clauwaert, K.M., Lambert, W.E., Deforce, D.L., Van den Eeckhout, E.G., De Leenheer, A.P., Liquid chromatography–mass spectrometry in forensic toxicology, *Mass Spectrometry Reviews* 19 (2000) 165-214.
15. Marquet, P., Is LC–MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology, *Therapeutic Drug Monitoring*, 24 (2002) 125-133.
16. Marquet, P., Progress of liquid chromatography–mass spectrometry in clinical and forensic toxicology, *Therapeutic Drug Monitoring*, 24 (2002) 255-276.
17. Zeleny, J., Instability of electrified liquid surfaces, *Phys. Rev.* 10 (1917) 1-6.
18. Dole, M., Mack, L.L., Hines, R.L., Mobley, R.C., Ferguson, L.D., Alice, M.B., Molecular beams of macroions, *J. Chem. Phys.* 49 (1968) 2240-2249.
19. Tal’Rose, V.L., Grishen, V.D., Skurat, V.E., Tantsyrev, G.D., Recent developments in mass spectroscopy, Ed. Ogata, K., Hayakawa T., University Park Press, Baltimore 1970.
20. Horning, E.C., Horning, M.G., Carroll, D.I., Dzidic, I., Stillwell, R.N., New pictogram detection system based on a mass spectrometer with an external ionization source at atmospheric pressure, *Anal. Chem.* 45 (1973) 936-943.

21. Arpino, P.J., Baldwin, M.A., McLafferty, F.W., Liquid chromatography–mass spectrometry. II. Continuous monitoring, *Biomed. Mass Spectrom* 1 (1974) 80-82.
22. Arpino, P.J., Dawkins, B.G., McLafferty, F.W., A liquid chromatography/mass spectrometry system providing continuous monitoring with nanogram sensitivity, *J. Chromatogr. Sci* 12 (1974) 574-578.
23. Iribarne, I.V., Thomson, B.A., On the evaporation of small ions from charged droplets, *J. Chem. Phys.* 64 (1976) 2287-2294.
24. Yamashita, M., Fenn, J.B., Electrospray ion source. Another variation on the free-jet theme, *Phys. Chem.* 88 (1984) 4451-4459.
25. Robb, D.B., Covey, T.R., Bruins, A.P., Atmospheric pressure photoionization: an ionization method for liquid chromatography–mass spectrometry, *Anal. Chem.* 72 (2000) 3653-3659.
26. Bruins, A.P., Covey T.R., Henion, J.D., Ion spray interface for combined liquid chromatography/atmospheric pressure ionization mass spectrometry, *Anal. Chem.* 58 (1987) 2647-2646.
27. Schmelzeisen-Redeker, G., Bütfering, L., Röhlgen, F.W., Desolvation of ions and molecules in thermospray mass spectrometry, *Int. J. Mass Spectrom. Ion Processes* 90 (1989) 139-150.
28. Hopfgartner, G., Bean, K., Henion, J., Henry, R., Ion spray mass spectrometric detection for liquid chromatography: a concentration- or a mass-flow-sensitive device?, *J. Chromatogr.* 647 (1993) 51-61.
29. Weinmann, W., Wiedemann, A., Eppinger, B., Renz, M., Svoboda, M., Screening for drugs in serum by electrospray ionization/collision-induced dissociation and library searching, *J. Am. Soc. Mass Spectrom.* 10 (1999) 1028-1037.
30. Marquet, P., Venisse, N., Lacassie, N., Lachâtre, G., In-source CID mass spectral libraries for the “general unknown” screening of drugs and toxicants, *Analysis* 28 (2000) 925-937.

31. Schreiber, A., Efer, J., Engewald, W., Application of spectral libraries for high-performance liquid chromatography–atmospheric pressure ionisation mass spectrometry to the analysis of pesticide and explosive residues in environmental samples, *J. Chromatogr. A* 869 (2000) 411-475.
32. Bogusz, M.J., Maier, R-D., Krüger, K.D., Webb, K.S., Romeril, J., Miller, M.L., Poor reproducibility of in-source collisional atmospheric pressure ionization mass spectra of toxicologically relevant drugs, *J. Chromatogr. A* 844 (1999) 409-418.
33. Lips, A.G.A.M., Lameier, W., Fokkens, R.H., Nibbering, N.M.M., Methodology for the development of a drug library based upon collision-induced fragmentation for the identification of toxicologically relevant drugs in plasma samples, *J. Chromatogr. B* 759 (2001) 191-207.
34. Hough, J.M., Haney, C.A., Voyksner, R.D., Bereman, R.D., Evaluation of electrospray transport CID for the generation of searchable libraries, *Anal. Chem.* 72 (2000) 2265-2270.
35. Weinmann, W., Stoertzel, M., Vogt, S., Wendt, J., Tune compounds for electrospray ionisation/in-source collision-induced dissociation with mass spectral library searching, *J. Chromatogr. A* 926 (2001) 199-209.
36. Weinmann, W., Stoertzel, M., Vogt, S., Svoboda, M., Schreiber, A., Tuning compounds for electrospray ionization/in-source collision-induced dissociation and mass spectral library searching, *J. Mass Spectrom.* 36 (2001) 1013-1023.
37. Bristow, A.W.T., Nichols, W.F., Webb, K.S., Conway, B., Evaluation of protocols for reproducible electrospray in-source collisionally induced dissociation on various liquid chromatography/mass spectrometry instruments and the development of spectral libraries, *Rapid Commun. Mass Spectrom.* 16 (2002) 2374-2386.
38. Dawson, P.H., Sun, W-F., A Round Robin on the reproducibility of standard operation conditions for the acquisition of library MS/MS spectra using triple quadrupoles, *Int. J. Mass Spectrom. Ion Processes* 55 (1983/1984) 155-170.

39. Martinez, R.I., Standard reference spectra for tandem mass spectrometry quality assurance, performance evaluation and proficiency testing: tandem mass spectrometers which use RF-only multipole collision cells, *Rapid Commun. Mass Spectrom.* 5 (1991) 245-248.
40. Weinmann, W., Gergov, M., Goerner, M., MS/MS libraries with triple quadrupole-tandem mass spectrometers for drug identification and drug screening, *Analisis* 28 (2000) 934-941.
41. Kienhuis, P.G.M., Geerdink, R.B., Liquid chromatography–tandem mass spectrometric analysis of surface and waste water with atmospheric pressure chemical ionization. II. Applications. *Trends Anal. Chem.* 19 (2000) 460-474.
42. Kienhuis, P.G.M., Geerdink, R.B., A mass spectral library based on chemical ionization and collision-induced dissociation, *J. Chromatogr. A* 974 (2002) 161-168.
43. Josephs, J.L., Characterization of over-the-counter cough/cold medications by liquid chromatography/electrospray mass spectrometry, *Rapid Commun. Mass Spectrom.* 9 (1995) 1270-1274.
44. Marquet, P., Dupuy J.L., Lachâtre, G., Shushan, B., Duchoslav, E., Monasterios, C., Ilisieu, P., Anacleto, J., Development of a “General Unknown” screening procedure using liquid chromatography–electrospray-mass spectrometry (LC–EC-MS), in: *Proc. 46th ASMS Conference on Mass Spectrometry and Allied Topics 1998*, Orlando, FL, 1998.
45. Slobodnik, J., Hogenboom, A.C., Vreuls, J.J., Rontree, J.A., van Baar, B.L.M., Niessen, W.M.A., Brinkman, U.A.Th., Trace-level determination of pesticide residues using on-line solid-phase extraction-column liquid chromatography with atmospheric pressure ionization mass spectrometric and tandem mass spectrometric detection, *J. Chromatogr. A* 741(1996) 59-74.
46. Sander, P., Substance identification of ion trap MS/MS spectra in a MS/MS library, in: *Proc. 47th ASMS Conference on Mass Spectrometry and Allied Topics 1999*, Dallas, TX, 2000.
47. Fitzgerald, R.L., Rivera, J.D., Herold, D.A., Broad spectrum drug identification directly from urine, using liquid chromatography–tandem mass spectrometry, *Clinical Chemistry* 45 (1999) 1224-1234.

48. Sanders, M., Josephs, J., Schwartz, J., Tymiak, A., DiDonato, G., Rapid identification of natural products using a modified ion trap mass spectrometer and MS/MS spectral library searching, in: *Proc. 47th ASMS Conference on Mass Spectrometry and Allied Topics 1999*, Dallas, TX, 2000.
49. Baumann, C., Cintore, M.A., Eichler, M., Lifante, E., Cooke, M., Przyborowska, A., Halket, J.M., A library of atmospheric pressure ionization daughter ion mass spectra based on wideband excitation in an ion trap mass spectrometer, *Rapid Commun. Mass Spectrom.* 14 (2000) 349-356.
50. Schreiber A., Gergov, M., Weinmann, W., Transfer of existing forensic LC/MS and LC/MS/MS mass spectral libraries to linear ion trap instrumentation, in: *Poster 52th ASMS Conference on Mass Spectrometry and Allied Topics 2004*, Nashville, TN, 2004.
51. Saint-Marcoux, F., Lachâtre, G., Marquet, P., Evaluation of an improved general unknown screening procedure using liquid chromatography–electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid chromatography-diode array detection, *J. Am. Soc. Mass Spectrom.* 14 (2003) 14-22.
52. Rittner, M., Pragst, F., Bork, W.-R., Neumann, J., Screening method for seventy psychoactive drugs or drug metabolites in serum based on high-performance liquid chromatography–electrospray ionization mass spectrometry, *J. Anal. Toxicol.* 25 (2001) 115-124.
53. Venisse, N., Marquet, P., Duchoslav, E., Dupuy, J.L., Lachâtre, G., A general unknown screening procedure for drugs and toxic compounds in serum using liquid chromatography–electrospray–single quadrupole mass spectrometry, *J. Anal. Toxicol.* 27 (2003) 7-14.
54. Fillion, J., Hindle, R., Lacroix, M., Selwyn, J., Multiresidue determination of pesticides in fruit and vegetables by gas chromatography–mass selective detection and liquid chromatography with fluorescence detection, *J. AOAC Int.* 78 (1995) 1252-1266.
55. Heinig, K., Henion J., Fast liquid chromatographic–mass spectrometric determination of pharmaceutical compounds, *J. Chromatogr. B* 732 (1999) 445-458.

56. Tong, X., Ita, I.E., Wang, J., Pivnichny, J.V., Characterization of a technique for rapid pharmacokinetic studies on multiple co-eluting compounds by LC/MS/MS, *J. Pharm. Biomed. Anal.* 20 (1999) 773–784.
57. Thieme, D., Grosse, J., Lang, R., Mueller, R.K., Wahl, A., Screening, confirmation and quantitation of diuretics in urine for doping control analyses by high-performance liquid chromatography–atmospheric pressure ionization tandem mass spectrometry, *J. Chromatogr. B* 757 (2001) 49–57.
58. Thieme, D., Sachs, H., Improved screening capabilities in forensic toxicology by application of liquid chromatography–tandem mass spectrometry, *Anal. Chim. Acta* 492 (2003) 171–186.
59. Josefsson, M., Kronstrand, R., Andersson, J., Romas, M., Evaluation of electrospray ionization liquid chromatography–tandem mass spectrometry for rational determination of a number of neuroleptics and their metabolites in human body fluids and tissues, *J. Chromatogr. B* 789 (2003) 151–167.
60. Jemal, M., Ouyang, Z., Zhao, W., Zhu, M., Wu, W.W., A strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability, *Rapid Commun. Mass Spectrom.* 17 (2003) 2732–2740.
61. Zhang, N., Fountain, S.T., Bi, H., Rossi, D.T., Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC/MS, *Anal. Chem.* 72 (2000) 800–806.
62. Zhang, H., Henion, J., Yang, Y., Spooner, N., Application of atmospheric pressure ionization time-of-flight mass spectrometry coupled with liquid chromatography for the characterization of in vitro drug metabolites, *Anal. Chem.* 72 (2000) 3347–3348.
63. Zhang, H., Heinig, K., Henion, J., Atmospheric pressure ionization time-of-flight mass spectrometry coupled with fast liquid chromatography for quantitation and accurate mass measurement of five pharmaceutical drugs in human plasma, *J. Mass Spectrom.* 35 (2000) 473–481.

64. Hopfgartner, G., Chernushevich, I.V., Covey, T., Plomley, B., Bonner, R., Exact mass measurement of product ions for the structural elucidation of drug metabolites with a tandem quadrupole orthogonal-acceleration time-of-flight mass spectrometer, *J. Am. Soc. Mass Spectrom.* 10 (1999) 1305-1314.
65. Decaestecker, T.N., Clauwaert, K.M., Van Bocxlaer, J.F., Lambert, W.E., Van den Eeckhout, E.G., Van Peteghem C.H., De Leenheer, A.P., Evaluation of automated single mass spectrometry to tandem mass spectrometry function switching for comprehensive drug profiling analysis using a quadrupole time-of-flight mass spectrometer, *Rapid Commun. Mass Spectrom.* 14 (2000) 1787-1792.
66. Bobeldijk, I., Vissers, J.P.C., Kearney, G., Major, H., van Leerdam, J.A., Screening and identification of unknown contaminants in water with liquid chromatography and quadrupole-orthogonal acceleration-time-of-flight tandem mass spectrometry, *J. Chromatogr. A* 929 (2001) 63-74.
67. King, R., Bonfiglio, R., Fernandez-Mezler, C., Miller-Stein, C., Olah, T., Mechanistic investigation of ionization suppression in electrospray ionization, *J. Am. Soc. Spectrom.* 11 (2000) 947-950.
68. Marquet, P., Saint-Marcoux, F., Camble, T.N., Leblanc J.C.Y., Comparison of preliminary procedure for the general unknown screening of drugs and toxic compounds using quadrupole-linear ion-trap mass spectrometer with liquid chromatography-mass spectrometry reference technique, *J. Chromatogr. B* 789 (2003) 9-18.
69. Müller, C., Schäfer, P., Störtzel, M., Vogt, S., Weinmann, W., Ion suppression effects in liquid chromatography-electrospray ionization transport-region collision induced dissociation mass spectrometry with different extraction methods for systematic toxicological analysis with mass spectral libraries, *J. Chromatogr. B* 733 (2002) 47-52.
70. Clarke's Isolation and Identification of Drugs, 2.p., Ed. Moffat, A.C., The Pharmaceutical Press, London 1986.

71. Osselton, M.D., Toxicological tables: a compendium of pharmacological, therapeutic and toxicological data on 136 drugs and chemicals on humans, *Bull. Int. Assoc. Forens. Toxicol.* 17 (1983) 16-33.
72. Stead, A.H., Moffat, A.C., A collection of therapeutic, toxic and fatal blood drug concentrations in man, *Human Toxicol.* 3 (1983) 437-464.
73. Pandurangi, A.K., Narasimhachari, N., Blackard, W.G., Landa, B.S., Relation of serum molindone levels to serum prolactin levels and antipsychotic response, *J. Clin. Psych.* 50 (1989) 379-381.
74. Jack, D.B., Handbook of Clinical Pharmacokinetic Data. Macmillan, Hants 1992.
75. Klamerus, K.J., Maloney, K., Rudolph, R.L., Sisenwine, S.F., Jusko, W.J., Chiang, S.T., Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite, *J. Clin. Pharmacol.* 32 (1992) 716-724.
76. Meyer, F.P., Indicative therapeutic and toxic drug concentrations in plasma: a tabulation, *Int. J. Clin. Pharm. Ther.* 32 (1994) 71-81.
77. Uges, D.R.A., Therapeutic and toxic drug concentrations, *Bull. Int. Assoc. Forens. Toxicol.* 26 (1996) (1 supplement) 1-34.
78. Schulz, M., Schmoldt, A., Therapeutic and toxic blood concentrations of more than 500 drugs, *Pharmazie* 52 (1997) 895-911.
79. Winek, C.L., Wahba, W.W., Winek Jr., C.L., Winek-Balzer, T., Drug and chemical blood-level data 2001, *Forensic Sci. Int.* 122 (2001) 107-123.
80. Maurer, H.H., Schmitt, C.J., Weber, A.A., Kraemer, T., Validated electrospray liquid chromatographic-mass spectrometric assay for the determination of the mushroom toxins alpha- and beta-amanitin in urine after immunoaffinity extraction. *J. Chromatogr. B* 748 (2000) 125-135.

81. Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Matrix effects in quantitative LC/MS/MS analyses of biological fluids: A method for determination of finasteride in human plasma at picogram per milliliter concentrations, *Anal. Chem.* 70 (1998) 882-889.
82. Rivier, L., Criteria for the identification of compounds by liquid chromatography–mass spectrometry and liquid chromatography–multiple mass spectrometry in forensic toxicology and doping analysis, *Anal. Chim. Acta* 492 (2003) 69-82.
83. Pelander, A., Ojanperä, I., Laks, S., Rasanen, I., Vuori, E., Toxicological screening with formula-based metabolite identification by liquid chromatography/time-of-flight mass spectrometry, *Anal. Chem.* 75 (2003) 5710-5718.